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1. GENERAL INTRODUCTION
Considerable attention over the years has been directed 
toward understanding the relationship between the central nervous 
system (CNS) and gastrointestinal (GI) ulceration. In particular 
the common association of stress-related gastric mucosal damage 
with CNS injury has supported the hypothesis that the CNS may 
play a significant role in controlling the structural integrity 
of the GI mucosa. It is well known that after intracranial 
diseases, head trauma, or CNS surgery patients are often 
afflicted with GI hemorrhage and acute ulceration known as 
"Cushing ulcer". Cushing in 1932 suggested such ulceration to be 
a result of vagal hyperactivity (Cushing, 1932) and gastric acid 
hypersecretion. This hypothesis has been further supported by the 
observation of increased gastric acid secretion in patients with 
CNS injury, an effect that is thought to be mediated by through 
effect on vagal nuclei in the medulla (Beattie, 1932; Cushing, 
1932) and centers in the hypothalamus (Heslop, 1938) . The 
establishment of the presence of a family of peptide in both the 
gut and the brain led to the speculation that these peptide may 
act as CNS neurotransmitters involved with the control of GI 
function. Studies examining the effects of intracerebral 
administration of such brain-gut peptide have demonstrated 
specific effects on gastric functions.
The vagus nerve with its sensory and preganglionic 
parasympathetic innervation to the abdominal viscera has long 
been in the focus of treatment for gastric ulceration considering 
its influence on gastric acid secretion. The presence of gastric 
acid was supposed to be required for the development of gastric 
erosions, thus the elimination of both efferent and afferent 
vagal effects on acid secretion through vagotomy has been widely 
used in gastric and duodenal ulcer therapy.
Based on the demonstration by Mozsik et al. that truncal 
vagotomy in turn aggravates gastric mucosal damage although the
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gastric acid secretion has been suppressed, the role of 
parasympathetic nervous system in the gastric lesion formation 
was widely investigated in acute and chronic vagotomized rats 
(Singh, 1980; Mozsik 1991; Cho 1992; Király 1992; Mozsik 1992a; 
Karadi 1994) . Several sets of experiments suggested a key role of 
vagal nerve in controlling GI integrity. We have shown that 
surgical vagotomy not only aggravates the gastric lesion 
formation in different experimental conditions (ethanol model- 
(Mozsik 1991) , indomethacin model-(Karadi 1994)) but also 
abolishes the gastric cytoprotection induced by prostaglandins, 
retinoids, acid inhibitors (omeprazole-(Cho 1992), cimetidinie- 
(Mozsik 1991; Cho 1992), atropine-(Mozsik 1991)) and adaptive 
cytoprotection (Henegan 1984). The unique ability of 
prostaglandins, in' particular PGE2, to prevent gastric mucosal 
injury elicited by a variety of experimental conditions 
independently of changes in gastric acid secretion was 
established by Robert et al (Robert 1978) and Chaudhury et al 
(Chaudbery 1978). The attenuation of antiulcer action of 
misoprostol and omeprazole was reported in vagotomized rats by 
using ex vivo stomach chamber technique (Cho 1992). These studies 
point to the importance of the vagal nerve in gastric 
cytoprotection by compounds eliciting their cytoprotective 
activity in different way (b-carotene - scavenger (Jávor 1983; 
Mozsik 1986), PGI2 - gastric mucus, bicarbonate secretion, 
promotion of repair mechanisms (Robert 1978) etc).
Therefore the effects of acute and chronic surgical vagotomy 
on gastric functions and defensive mechanisms (blood flow (Cho 
1992) gastric emptying (Mozsik 1992a), vascular permeability 
(Király 1992), mucosal prostaglandin production (Bodis 1990; Suto 
1992)) of the stomach were widely investigated by us.
1.1 TRH in the dorsal vagal complex (DVC) stimulates vagal 
outflow to the stomach and gastric functions
Although multitude of chemical systems in the CNS can 
influence different gastric functions through vagal dependent 
mechanisms, still little is known about the physiological role of 
these transmitters in the vagal regulation of gastric function. 
During the last decade, much attention has been focused on the 
three amino acid peptide, thyrotropin-releasing hormone (TRH). 
TRH was the first brain peptide shown to affect gut function 
after central administration (Tache 1980) . When TRH was first 
identified in 1970, it was assumed the it served a specific 
function in the hypothalamo-hypophyseal axis.
The initial report that TRH potently stimulates central 
vagal dependent gastric acid secretion in rats (Tache 1980) was 
followed by growing neuroanatomical and neuropharmacological 
information on central TRH actions influencing GI functions 
through vagal pathways in different species of experimental 
animals (Goto 1985; Tache 1988; Ishikawa 1988; Tache 1994a). 
Furthermore it was clearly shown that TRH action in the medulla 
completely independent of its hypophysiotropic action (Tache 
1980) .
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1.1.1 Distribution of TRH-like Immunoreactivity (TRH-LI) and 
TRH Receptors in the Dorsal Vagal Complex (DVC)
The distribution of THR-like immunoreactivity (TRH-LI) in 
the brain stem supports an important role of the tripeptide in 
the regulation of vagal activity to the stomach. Nearly 65% of 
total medullary TRH-LI is located in nuclei associated with the 
dorsal vagal complex (DVC, composed of the dorsal motor nucleus 
of the vagus (DMN) and the nucleus of the solitary tract (NTS)) 
(Eskay 1983; Hornby 1989). In the DVC, TRH-LI is found 
exclusively in varicose and nonvaricose segments of unmyelinated
axons and in presynaptic terminals (Brownstein 1974; Tache 
1994a).
Electronmicroscopy studies have shown that gastric 
preganglionic neurons contain rich dendritic arborization which 
reach the nucleus subgelatinosus in the medial NTS and make 
monosynaptic contact on gastric vagal sensory neuron terminals 
providing the basis of vago-vagal reflex (Rinaman 1989; Tache 
1994a). Double-labeling techniques performed in rats have 
demonstrated the existence of direct asymmetric synaptic contacts 
(indicative for excitatory synapse) between TRH-LI containing 
terminals and dendrites of gastric motoneurons coursing 
throughout the DMN and medial NTS mainly in the subnucleus 
gelatinosus immediately caudal to the obex (Eskay 1983). In 
addition, the presence of nonsynaptic TRH-LI varicosities 
suggests a possible role of paracrine neuromodulating role in the 
DVC. Such localization of TRH-LI in the DVC is not unique to rats 
and has also been reported in the cat medulla (Hornby 1989).
The distribution of TRH receptors in the DVC well correlates 
with the presence of TRH-LI in the nerve terminals. The highest 
concentration of TRH receptors is located in the medial part of 
the DMN containing preganglionic vagal neurons innervating the 
stomach and influencing gastric function (Laughton 1987; Wu 
1992) .
TRH receptors are also found in the lateral column of the 
DMN contributing to the celiac branch of the vagus, as well as in 
the nucleus subgelatinosus, medial subnuclei of the NTS, and area 
postrema (Wu 1992) . The presence of TRH receptors in neurons of 
the DMN and NTS was further established by in situ hibridisation 
technique usd,ng mRNA coding for mice pituitary TRH receptor (Wu 
1992) .
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1.1.2 Excitatory Effect of TRH on DMN Motorneurons and Vagal 
Efferent Activity
The morphological demonstration of asymmetric synapses 
indicates functional excitatory input between TRH-LI presynaptic 
terminals and gastric motoneuronal dendrites which was confirmed 
by electrophysiological studies (McCann 1989; Rogers 1989; 
Ragenbass 1990). TRH increases the firing rate of DMN neurons 
either in vivo or in vitro (McCann 1989; Rogers 1989; Ragenbass 
1990). The response assessed in vitro was not altered by 
inhibition of synaptic transmission showing that TRH exerts a 
direct postsynaptic excitatory effect on DMN neurons (Ragenbass 
1990) . Regarding the influence of TRH on NTS neurons, an 
inhibitory effect was reported in vivo on neurons responding to 
gastric inflation (Rogers 1989). By contrast in an in vitro slice 
tissue preparation, TRH consistently induced a reversible 
excitatory effect which persists in the presence of blockade of 
synaptic transmission (Ragenbass 1990). Whether the inhibitory 
action of TRH on NTS neurons in vivo represents an indirect 
action needs to be further investigated.
TRH applied directly to the DMN was shown to increase the 
parasympathetic outflow to various viscera. Injection of TRH or 
stable TRH analog, RX 77368 [p-Glu-His-(3,3'dimethyl)-Pro-NH2] , 
in the cerebrospinal fluid (CSF) stimulates vagal efferent 
activity recorded from the cervical, gastric, superior laryngeal, 
and ciliar branches of the vagus (Somiya 1984; 0-Lee 1997).
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1.1.3 TRH in the DMN Induces a Vagal Dependent Stimulation 
of Gastric Function
Microinjection of TRH or the stable TRH analog RX 77368, in 
the DMN induced a vagal dependent stimulation of gastric acid and 
pepsin secretion and gastric mucosal blood flow (GMBF) in
anesthetized rats (Tache 1980; Tache 1988; Ishikawa 1988; Thiefin 
1989; Yanagisawa 1990a; Yang 1992; Király 1994) or cats (Feng 
1990). Based on the biological response the DMN seems to be more 
responsive than any other medullary site (Tache 1994a) . 
Microinjection of TRH or RX 77368 in the DMN also induced a vagal 
muscarinic stimulation of gastric motor function assessed by an 
increase in corpus tone and phasic high-amplitude contractions, 
and antral and pylorus contractility in rats (Madea-Hagiwara 
1987; Garrick 1987; Tache 1994a) and cats (Rinaman 1989).
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1.2 Influence of central vagal activation by TRH on gastric 
secretion: functional implications
1.2.1 Increase in Gastric Secretion
1.2.1.1 Histamine
There is an evidence that intracisternal injection of TRH 
stimulates histamine release as assessed by the increase of 
histamine levels in the portal blood or gastric interstitial 
fluid or fundic submucosa in anesthetized rats (Fig. 1) 
(Yanagisawa 1990a; Tache 1994a). The portal release of histamine 
induced by central TRH analog is mediated by vagal muscarinic 
pathways independently from gastrin (Yanagisawa 1990a).
1.2.1.2 Serotonin
Serotonin concentration of the portal blood and fundic 
submucosa is markedly increased for sustained periods of time 
upon injection of TRH or stable analog in the cisterna magna or 
DMN (Stephens 1989; Yang 1992) . The stimulation of gastric 
serotonin by central injection of RX 77368 is mediated by vagal 
muscarinic pathways and is not related to the increase in acid 
secretion (Stephens 1989; Yang 1992) (Fig. 1).
The relative contribution of the various cellular pools of 
gastric serotonin in the luminal release is not clear. Gastric 
stores of serotonin are localized in endocrine (enterochromaffin
and "enterochromaffin-like" cells), mast cells and enteric 
neurones (Stephens 1989) . Rat gastric enterochomaffin-like cell 
readily synthesize and store serotonin, in addition , gastric 
mast cell degranulation has been correlated with the increased 
intraluminal serotonin release (Stephens 1989; Yang 1992; Tache 
1994a) and decreased mast cell serotonin levels.
1.2.1.3 Prostaglandins
Early studies demonstrated that direct electrical 
stimulation of the vagus nerve increases PGE,, PGE2, PGF,„ and PGF2o 
levels in venous and luminal effluent of totally isolated 
vascularly perfused rat stomach (Singh, 1980) . Similarly acute 
surgical vagotomy decreased the gastric mucosal content of 6- 
keto-PGFla, and PGI2 (Bodis 1990; Suto 1992) .
Intracisternal injections of TRH or RX 77368 induced a dose- 
related release of PGE2 (Fig. 1) which is mediated through vagal 
muscarinic mechanisms not related to the stimulation of acid 
secretion (Yoneda 1993b). Bilateral cervical vagotomy completely 
prevented PGE2 release into the interstitial fluid of the corpus 
submucosa (Yoneda 1993b) after central RX 77368. The endogenous 
gastric prostaglandins are biologically active to suppress 
gastric acid secretion when submaximal doses of TRH are used 
(Yoneda 1993b).
1.2.1.4 Nitric Oxide
Central vagal activation by TRH analog stimulates nitric 
oxide (NO) (Király 1993; Tanaka 1993) release (Fig. 1) from the 
endothelium in blood vessels of the gastric mucosa. This is 
supported by the demonstration that the stimulation of gastric 
mucosal blood flow or gastric cytoprotection induced by 
intracisternal injections of TRH analog are completely prevented 
by the nitric oxide synthesis inhibitor, N-nitro-L-arginine 
methyl ester (L-NAME) (Tanaka 1993).
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Mg. 1. Schematic illu stra tio n  of the activation of dorsal vagal conplex (DVC) and peripheral action of 
thyrotropin releasing hormone ( TRtl) injected in tracistem ally  (myenteric plexus (HP), prostaglandin F, 
(PGf,) .  b-hydroxy-tryptamine (S -III). n it r ic  oxide (NO))
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1.2.2 Functional Implications
1.2.2.1 Acid Secretion
A stimulation of gastric acid secretion was suggested after 
central injection of TRH or stable TRH analog in a dose- 
dependent manner (Tache 1980; Ishikawa 1988; Yang 1990). The site 
of action of TRH or stable analog was suggested to be in the 
nucleus ambiguus and DVC or raphe pallidus (Ishikawa 1988; Yang 
1990). These results also suggest a role for these nuclei and TRH 
in the medullary regulation of gastric acid secretion.
At maximal effective dose (30 ng) , more than half of the acid 
response is mediated through vagal muscarinic release of gastric 
histamine acting on H2 receptors. The remaining component most 
likely involves a direct muscarinic action of acetylcholine on 
the parietal cells whereas gastrin does not play role (Yanagisawa 
1990a; Tache 1994a) (Fig. 1) . At submaximal effective doses of 
TRH injected intracisternally, however, the gastric acid response 
represents the net effect of released inhibitors such as 
prostaglandins and serotonin and stimulants such as histamine and 
acetylcholine interacting on the parietal cells (Ishikawa 1988; 
Yanagisawa 1990a; Yoneda 1992) (Fig. 1).
1.2.2.2 Motor Functions
There is a marked stimulation of gastric motor activity and 
gastric emptying upon central injection of TRH which is mediated 
by vagal muscarinic pathways (Garrick 1987; Madea-Hagiwara 1987; 
Tache 1990; Okumura 1995). Peripheral mechanisms of the motor 
response may also involve an interplay between the inhibitory 
(serotonin) and stimulatory (acetylcholine) influence of various 
neurotransmitters released (Fig. l).
1.2.2.3 Gastric Mucosal Blood Flow
Intracisternal TRH or RX 77368 are well established to
increase gastric mucosal blood flow (GMBF) through vagal 
muscarinic pathways (Thiefin 1989; Tanaka 1993) . Such gastric
hyperemia is independent of the increase in acid secretion since 
the hyperemic effect of central RX 77360 was not influenced by 
omeprazole-pretreatment (Thiefin 1989) . The increase in GMBF is 
mainly mediated through nitric oxide pathways (Tanaka 1993).
1.2.2.4 Gastric mucosal resistance to acid (gastric mucus 
gel thickness, increased intraepithelial pH)
Intracisternal RX 77368 was shown to increase gastric mucus 
gel thickness, surface epithelial cell intracellular pH, HC03' 
delivery and H+ removal in the subepithelial interstitial space 
abutting the surface cells (Tache 1994a; Tanaka 1997). The 
mechanism through' which central vagal activation increases 
gastric mucus gel thickness is independent from the prostaglandin 
secretion and probably mainly directly mediated by cholinergic 
pathways (Tache 1994a; Tanaka 1997).
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1.2.2.5 Ulcer Formation and Protection
Recent studies have shown that intracisternal injection of 
TRH analog at low doses induces cytoprotection against gastric 
lesions induced by ethanol through vagal muscarinic release of 
prostaglandin E2 (Madea-Hagiwara 1987; Yoneda 1992; Yoneda 1993b; 
Tache 1994b; Kaneko 1995a; Kaneko 1995b; Kato 1996). By contrast, 
central injection of TRH at maximal effective doses to stimulate 
gastric function leads to formation of gastric hemorrhagic 
lesions in fasted rats (Goto 1985; Tache 1988; Tache 1993b). 
Central sites of action have been located in the DVC and central 
amygdala (Tache 1994a).
Several data indicate that medullary TRH plays a role in 
cold restraint stress-induced gastric lesions. Central injection 
of TRH-antibody prevents gastric lesion formation induced by cold 
restraint (Yang 1994). Cold restraint induced an increase in TRH
gene expression and neuronal activation was observed as monitored 
by the appearance of c-fos immunoreactivity in nuclei raphe 
pallidus and obscurus (Yang 1994).
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2. AIM AND OUTLINE OF THE THESIS
2.1. Studies on gastric cytoprotection
Pioneer findings by Robert et al established the unique 
ability of prostaglandins, in particular PGE2, to prevent gastric 
mucosal injury elicited by a variety of experimental conditions 
independently of the changes in gastric acid secretion (Robert 
1978) .
The role of the parasympathetic nervous system in the development 
of gastric cytoprotection was investigated since:
(1.) either acute' or chronic surgical vagotomy aggravates the 
gastric mucosal lesion formation in experimental ulcer models 
(Mozsik 1991; Mozsik 1992a; Király 1992; Karadi 1994),
(2.) the activation of the vagus elicits gastric cytoprotection 
through prostaglandins (Yoneda 1992; Yoneda 1993b).
The aims of gastric cytoprotection studies were:
(1.) to investigate the action of TRH in the medulla to induce 
vagally-mediated gastric cytoprotection against ethanol,
(2.) to investigate the final peripheral mediators particularly 
the role of nitric oxide in the development of gastric 
cytoprotection induced by central vagal stimulation.
2.2 Vagal regulation of gastric functions: blood flow and acid 
secretion studies
The mechanisms involved in the vagal regulation of gastric 
mucosal blood flow were previously investigated by using 
electrical stimulation of the vagus nerve (Guth 1987). The 
associated stimulation of gastric acid secretion was originally 
postulated to account for the gastric hyperemic response (Guth
1987). However in vivo microscopy technique provided evidence 
for direct vasodilatory effect on gastric submucosal arterioles 
mediated by atropine-sensitive and atropine-resistant mechanisms 
observed at high frequencies of vagal stimulation (Morishita 
1986; Guth 1987; Thiefin 1990). Since electrical stimulation of 
the vagal nerve trunk induced orthodromic as well as antidromic 
activation of vagal fibers (Thiefin 1990), injection into the 
cerebrospinal fluid of TRH or the stable analog, RX 77368, 
provides more relevant physiological tool to gain insight into 
the peripheral mechanisms underlying vagal-dependent stimulation 
of GMBF.
Although it is well established that central vagal 
activation produces hyperemia in the stomach, the peripheral 
mediators inducing the hyperemic effect are little known. Several 
vasoactive substances including acetylcholine, prostaglandins, 
histamine, VIP, nitric oxide, CGRP are candidates for peripheral 
mediator(s) of vasodilation during central vagal activation, 
since each of them were shown to be released after central 
injection of TRH or RX 77368 (Thiefin 1989; Lenz 1989; Yanagisawa 
1990a; Thiefin 1990; Yoneda 1993b; Messmer 1993; Tanaka 1993).
The aims of gastric mucosal blood flow studies were to 
investigate:
(1.) the effect of intracisternal (ic) TRH analog, RX 77368 
injected at maximal effective dose stimulating gastric acid 
secretion (30 ng) and at cytoprotective dose (1.5 ng) , on the 
changes of GMBF, systemic blood pressure -mean arterial pressure 
(MAP)-, and gastric mucosal vascular resistance (GMVR) determined 
by a technique known to reflect only changes in gastric 
microcirculation (hydrogen gas clearance technique) (Leung 1984; 
Guth 1987; Livingston 1989),
(2.) the contribution of neuropeptides located in primary sensory 
neurons in the gastric submucosa to the increase in GMBF induced 
by intracisternal injection of maximal effective dose (30 ng) of 
TRH analog or peripheral cholinergic stimulation,
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(3.) the nature of mediators participating in gastric hyperemia 
induced by ic injection of RX 77368 at 30 ng, to determine 
whether gastric hyperemia is muscarinic in nature or whether 
additional, atropine-resistant mechanisms also participate as 
observed with electric vagal stimulation (Guth 1987),
(4.) whether the atropine-dependent response is mediated by 
histamine and/or nitric oxide,
(5.) whether non-adrenergic-non-cholinergic neuropeptides such as 
vasoactive intestinal polypeptide (VIP ) or tachykinins 
contribute in the action of central RX 77368 on the gastric 
microvasculature,
(6.) the effect of a cytoprotective (or threshold (0-Lee 1997)) 
dose (1.5 ng) of RX 77368 on gastric mucosal microcirculation and 
gastric acid secretion,
(7.) the role of prostaglandins and CGRP contained in capsaicin 
sensitive sensory afferent fibers in mediating or modulating GMBF 
and gastric acid secretory responses to intracisternal injection 
of RX 77368.
Furthermore we examined the antagonist action of recently 
synthesized vasoactive intestinal polypeptide (VIP) receptor 
antagonist, (4C1-D-Phe8, Leul7)VIP, on VIP-induced systemic and 
gastric vascular changes, and central vagal stimulation-induced 
gastric mucosal hyperemia and gastric acid secretion.
2.3 Investigation of the contribution of mucosal immune system in 
the effects of central vagal activation: brain-immune system axis
Cholinergic-mediated gastric mast cell degranulation has
been shown during stress (Cho 1979). Electric vagal stimulation 
was reported to induce an enhancement of mast cell activation in 
the rat stomach (Guth 1987). Furthermore, i.c. TRH analog 
increased the release of rat mast cell protease II (RMCPII) in 
the rat ileum through vagal muscarinic pathways (Saperas 1994). 
RMCPII is a specific marker for activated mucosal mast cells 
(MMC) .
On the other hand consistent association of mast cells and 
nerve endings containing either substance P or CGRP was 
demonstrated in the skin, myocardium, ileum, mesentery and 
diaphragm (Stead 1987) of variety of animals.
Therefore the special aim of the studies were to asses the 
contribution of mucosal immune cells in the gastric mucosal 
hyperemia and gasbric acid secretion induced by central vagal 
activation.
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3. METHODS, RESULTS AND DISCUSSIONS
3.1 Studies on gastric cytoprotection
3.1.1 The role of nitric oxide in the gastric cytoprotection 
induced by central vagal stimulation
3.1.1.1 Background
Central thyrotropin-releasing hormone (TRH) is well known to 
induce a vagal-dependent, muscarinic-mediated stimulation of 
different gastric functions in rats and cats (Tache 1988). 
Intracisternal (i.c.) injection of the stable TRH analog, RX 
77368, was shown to prevent ethanol-induced gastric lesions in 
rats (Yoneda 1992; Tache 1994b; Kato 1994; Kaneko 1995a; Kato 
1996) . The cytoprotective effect involved muscarinic and 
prostaglandin mediated mechanisms (Yoneda 1993b; Tache 1994b; 
Kato 1996). Maintaining or increasing gastric mucosal blood flow 
plays an important role in gastric protection against injurious 
agents (Whittle 1990; Holzer, 1992b). TRH or RX 77368 injected 
i.c. stimulates gastric mucosal blood flow through muscarinic- 
and nitric oxide (NO)-dependent pathways (Thiefin 1989; Tanaka 
1993). Since there are convergent evidence that NO is involved in 
the maintenance of the integrity of the gastric mucosa 
(MacNaughton 1989; Lopez-Belmonte 1992), the present study tests 
the hypothesis that the L-arginine-NO pathway plays a role in the 
gastric cytoprotection produced by i.c. injection of RX 77368 in 
rats.
3.1.1.2 Materials and methods
The following drugs were used: L-I^-nitro-arginine methyl 
ester (L-NAME) and L- or D- arginine (Sigma Chemical, St Louis, 
MO), RX 77368 [p-Glu-His-(3,3'-dimethyl)-Pro-NH2] , (Reckitt & 
Colman, Kingston-upon-Hill, England), and ethanol (Fisher
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Scientific, Fair Lawn, NJ) . Drugs were diluted in 0.9% saline, 
except ethanol, which was diluted in distilled water, injections 
into the cisterna magna or the jugular vein were given in volumes 
of 10 /xl/rat and 0.3 ml/rat, respectively, under light ether 
anesthesia as described previously (Yoneda 1993b).
Male Sprague-Dawley albino rats (220-240 g, Harlan 
Laboratories, San Diego, CA) were fasted overnight but allowed 
water ad libitum up to the beginning of the experiments. Rats 
were injected i.v. with saline or L-NAME (3 mg/kg) immediately 
before i.c. injection of saline or RX 77368 (1.5 ng) . Additional 
groups of rats were injected i.v. with either L- or D-arginine 
(500 mg/kg) or saline immediately before L-NAME. In a separate 
experiment, groups of rats were injected i.v. with L-arginine 
(100-500 mg/kg) or D-arginine (500 mg/kg). Ethanol (60%, 1 ml) 
was administered intragastrically to conscious rats 30 min after 
i.c. or i.v. injections. The choice of doses for each treatment 
was based on our previous studies (Yoneda 1992; Yoneda 1993b; 
Tanaka 1993) . Rats were killed by C02 inhalation 60 min after 
ethanol administration, and stomachs were removed, opened along 
the greater curvature, gently rinsed in 0.9% saline, and pinned 
open to expose the mucosa. The percentage of corpus mucosa 
containing lesions was determined by means of a computerized 
image analyzer device (MICRO/PDP-11, Digital Equipment Corp., 
Maynard MA) , equipped with imaging boards (Imaging Technology 
Inc., Woburn MA) as described previously (Yoneda 1992).
Results are expressed as means ± S.E.M. A one way analysis 
of variance (ANOVA) followed by Duncan's contrast were used to 
compare the differences between groups. P value < 0.05 was 
considered to be statistically significant.
3.1.1.3 Results
Oral administration of 1 ml of 60% ethanol to rats injected 
i.c. with saline produced macroscopic lesions covering 10.7 ± 
1.8% of the total surface of the corpus mucosa (Fig. 2). L-NAME
alone did not increase significantly the extent of mucosa damage 
induced by ethanol (13.8 ± 1.8%). RX 77368 injected i.c. at 1.5 
ng 30 min before ethanol instillation reduced by 88% the extent 
of gastric mucosa injury (1.3 ± 0.3%) . The gastric cytoprotection 
induced by RX 77368 was completely abolished by i.v. injection of 
3 mg/kg L-NAME (11.9 ± 1.9%). The effect of L-NAME was
antagonized by i.v. injection of 500 mg/kg of L-arginine (3.5 ± 
1-4%) but not by D-arginine (10.3 ± 3.3%) (Fig. 2). The highest 
dose of L-arginine (500 mg/kg) alone protected the gastric mucosa 
against ethanol (2.7% ± 0.8%) whereas the lower doses (100 and 
300 mg/kg) and D-arginine (500 mg/kg) were ineffective (Fig. 3).
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Tig. ? .  Fffect of I -NAMf on i . c .  RX //36fl-induced gastric  cytoprotection in ethanol-treated rats, 
freatmonts (vehicle:!).9X NaCl: 0 .1 ml iv, white coliuns; l -N/Yfl : 3 mg/kg iv. black colum: I-arginine: 
500 mg/kg iv +1 -N/iMl : 3 mg/kg iv. obi ique str ip  column; D-arginine: 500 mg/kg iv + I -NAMf : 3 mg/kg iv. 
vertical s tr ip  column) were given 30 min before intragastric actainistration of ethanol (60X. 1 ml). Fach 
colimn represents the mean ± S .l M. of 7-11 rats per grouj). ' P< 0.05 vs. i . c .  saline plus ethanol.
Király, 28
20
15
o
4)k.<
-oVü>o
Eoo
10
5
0
i-----------------------1-----------------------1------- -- i r -
0 100 3 0 0  5 00
Ar g in in e  ( m g / k g ,  i .v. )
0 .9% NnCl  ( 0 . 0
L - a r g l n i n e
D - a r g i n i n e
r n l , i . v . )
— I—
5 0 0
1
Mg. 3. i ífe c t s  of I - or I) arginine on the development of ethanol induced gastric  mucosa lesions. Vehicle 
CO.9* NaCl: 0.3 ml iv. white colum ). 1-arginine (100 . 300 or 500 mg/kg iv. black coluins) and D-arginine 
(500 mg/kg iv. s tr ip  colum ) were given 30 min before ig ethanol (60*. 1 ml), fach colum represents the 
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3.1.1.4 Discussion
In agreement with our previous report, i.c. injection of a 
low dose of TRH analog RX 77368 protects the gastric mucosa 
against ethanol-induced damage (Yoneda 1992). The cytoprotective
effect of i.c. injection of RX 77368 was shown to be mediated 
through central vagal cholinergic pathways (Yoneda 1992). In the 
present study, L-NAME, injected i.v. at a dose that has 
previously been established to inhibit NO synthesis from L- 
arginine (MacNaughton 1989; Tanaka 1993), did not influence 
ethanol-induced gastric lesions while it completely abolished the 
cytoprotective effect of RX 77368. The action of L-NAME was 
reversed in an enantiomerically specific manner by L- but not D- 
arginine. These results indicate a role for the L-arginine NO 
pathway in mediating the cytoprotective effect of centrally 
injected TRH analog. This is further supported by evidence that 
central vagal activation by i.c. RX 77368 increases gastric NO 
formation (Tanaka 1993; Tanaka 1997) . In addition, i.v. injection 
of the NO precursor, L-arginine, prevents ethanol-induced gastric 
lesions whereas the D-arginine, which does not induce NO 
synthesis, had no effect. L-arginine given i.v. is also reported 
to provide protection against HC1-induced gastric damage (Tanaka 
1997) and other NO donors to reduce gastric lesions induced by 
endothelin-1 and ethanol in an ex vivo chamber preparation of the 
rat stomach. In addition, there is evidence that inhibition of NO 
synthesis prevents intragastric capsaicin- and calcitonin-gene 
related peptide-induced protection against ethanol (Lambrecht 
1993) . Taken together, previous and present findings provide 
convergent evidence for a role of NO in the protection of the 
gastric mucosa against injury.
The mechanisms through which NO mediates i.c. RX 77368- 
induced cytoprotection probably involve an action on the 
microvasculature. NO is a potent vasodilator (Palmer 1988) and 
the maintenance of gastric microcirculation is a key element in 
the resistance to ethanol injury (Whittle 1990). In addition, we 
previously demonstrated that i.c. RX 77368 increases gastric 
mucosal blood flow through muscarinic NO-dependent pathways 
(Thiefin 1989; Tanaka 1993) . Since we previously found that 
prostaglandins and calcitonin gene-related peptide also 
participate in the cytoprotective effect of i.c. RX 77368 (Yoneda
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1993b; Kató 1994; Tache 1994b; Kató 1996), the demonstration of 
an involvement of NO pathways further supports the concept that 
an interaction exists between NO, prostanoids and sensory peptide 
in the regulation of mucosal integrity as reported by Whittle et 
al. (Whittle 1990).
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3.2 Vagal regulation of gastric functions: blood flow and acid 
secretion studies
3.2.1 Central vagal activation by TRH induces gastric 
hyperemia: role of CGRP in capsaicin-sensitive afferents in rats
3.2.1.1 Background
TRH or its stable analog, RX 77368, injected into the 
cisterna magna or the dorsal vagal complex, enhances the efferent 
activity of the gastric branch of the vagus nerve leading to 
vagal stimulation of gastric secretory and motor function (Somiya 
1984; Garrick 1987; Madea-Hagiwara 1987; Tache 1988; Tache 1990; 
Tache 1993a; Chan 1995) . Central injection of TRH also increases 
gastric mucosal blood flow (GMBF) through vagal dependent 
pathways (Okuma 1987; Ishikawa 1988; Thiefin 1989; Raybould 1990; 
Tanaka 1993) . Electrical vagal stimulation increases GMBF 
through cholinergic and non cholinergic components (Morishita 
1986; Thiefin 1990) . However, the increase in GMBF in response
to central injection of TRH is solely mediated by vagal 
cholinergic dependent mechanisms (Thiefin 1989) . It has been 
reported previously that the gastric hyperemic response to 
intracisternal injection of TRH or TRH analog is not a secondary 
event to the vagal stimulation of gastric acid secretion (Thiefin 
1989), but represents a direct vasodilatory response mediated by 
muscarinic and nitric oxide dependent mechanisms (Thiefin 1989; 
Tanaka 1993).
In the rat skin microvasculature, acetylcholine-induced 
vasodilation involves both nitric oxide and capsaicin-sensitive 
components (Ralevic 1992). Anatomical and functional
observations are consistent with the possibility that the gastric 
hyperemia resulting from central vagal cholinergic activation may 
also involve the recruitment of capsaicin-sensitive afferent 
fibers. First, capsaicin-sensitive primary sensory neurons, which
contain a-calcitonin-gene related peptide, innervate the 
vasculature and form a dense plexus around arterioles and small 
arteries of the mucosa and submucosa in the rat stomach 
(Sternini, 1992) . Second, o-CGRP is well established as one of 
the most potent stimulants of GMBF in rats (Holzer 1991a) . 
Lastly, recent reports indicate that the gastric vasodilatory and 
cytoprotective effects of a-CGRP involve nitric oxide dependent 
pathways (Holzer 1993; Lambrecht 1993).
In the present study, we assessed the contribution of CGRP 
located in primary sensory neurons to the increase in GMBF 
induced by intracisternal injection of TRH or peripheral 
cholinergic stimulation.
'w
3.2.1.2 Materials and methods
Animal Preparations
Male Sprague-Dawley rats (Harlan Laboratories, San Diego, 
CA) weighing 250-275 g were housed under conditions of controlled 
temperature (20± 3°C) and illumination (12-h light cycle starting 
at 6 AM) . Rats were maintained on Purina Laboratory Rat Chow 
(Ralston Purina, St. Louis, MO) and tap water ad libitum. The 
food was withheld for 24 h before the experiment, but water was 
given ad libitum. All experiments were performed in rats 
anesthetized with urethane (1.25 g/kg i.p.). Rectal temperature 
was maintained between 36-37°C throughout the duration of 
experiments with heat lamps.
Drugs and Treatments
The following substances were used: the stable TRH analog, 
RX 77368, [p-Glu-His-(3,3'-dimethyl)-Pro-NH2; Reckitt & Colman, 
Kingston-upon-Hill, England] ; the CGRP receptor antagonist, human 
CGRP^, thCGRPg.37; Institute National de Recherche en Santé, 
University of Quebec, Pointe-Claire, P.Q., Canada]; rat or-CGRP 
[Clayton Foundation Laboratories, The Salk Institute, La Jolla,
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CA]; substance P (NK,) receptor antagonist, CP-96,345, [Pfizer 
Inc., Groton, CT]; and bethanechol chloride [Merck Sharp & Dohme, 
West Point, PA] . All other chemicals were obtained from Sigma 
Chemical Co., (St. Louis, MO). RX 77368 was aliquoted in 0.1% 
bovine serum albumin (BSA) containing 0.9% saline at a 
concentration of 3 (ig/10 fil and kept frozen at -20° C. The stock 
solution was dissolved in 0.9% saline (pH=7.0) before 
administration. CGRPg.37 and CP-96,345 were dissolved in 0.1% BSA 
containing 0.9% saline. Capsaicin was dissolved in absolute 
ethanol, Tween 80 and isotonic saline, 10:10:80:v/v/v. In rats 
under light ether anesthesia, capsaicin was injected s.c. three 
times at 12 h intervals at doses of 25, 50 and 50 mg/kg, 
respectively. The control group received the same regimen of 
injections except that the vehicle instead of capsaicin was 
administered. Experiments were performed 10-14 days after 
completion of the vehicle or capsaicin pretreatment in rats that 
showed the disappearance of the corneal chemosensory reflex to a 
drop of a 0.1% NH40H instillated into both eyes.
Surgical Procedures
Placement of catheter into the cistema magna.
The head was fixed in a stereotaxic instrument (Kopf model 
900) and the atlanto-occipital membrane was exposed. With the 
help of a dissecting microscope, a small pin hole was made into 
the membrane with a 25 G needle at 1-1.5 mm distal to the caudal 
edge of the occipital bone. Then a PE-10 polyethylene catheter 
(length: 10 cm; dead space: ca 5 ill) was inserted through the 
hole into the cisterna magna. The catheter was connected to a 50 
li 1 Hamilton microliter syringe. Successful cannulation was 
verified by leakage of cerebrospinal fluid (CSF) from the 
catheter. A drop of cyanoacrylate (Crazy Glue, Itasca, 111) was 
used to hold the catheter in position. Intracisternal injection 
of RX 77368, (30 ng in 10 nl volume) was followed by a 10 n 1
injection of saline to flush the catheter.
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Tracheal cannula and other vessels.
After cannulation of the cisterna magna, a tracheotomy was 
performed to facilitate ventilation and enable the administration 
of hydrogen and the esophagus was ligated. A PE-50 catheter was 
placed into the femoral artery for monitoring blood pressure with 
a Statham P23 Dd transducer. Another PE-50 catheter was inserted 
into the jugular vein to deliver drugs either for bolus injection 
(0.3 ml over 30 sec) and infusion (1.5 ml/h) to maintain 
hydration. Close intra-arterial infusion was performed by 
inserting retrogradely a PE-10 catheter into the splenic artery 
close to the celiac artery. The infusion volume into the splenic 
artery was 25 ^tl/min.
Gastric cannula.
To avoid the backdiffusion of gastric acid secretion 
stimulated after RX 77368 injection, the stomach was cannulated 
as follows. After a midline laparotomy, the stomach was 
exteriorized, the pylorus was ligated and an incision was made in 
the forestomach to insert a double-lumen cannula (outer Tygon 
tube and inner polyethylene catheter 7 mm and inner 2 mm 
diameter, respectively) which was secured by ligature. 
Physiological saline at room temperature was infused by the inner 
cannula at a rate of 0.5-0.7 ml/min. The effluent was 
continuously collected by flow drainage from the outer tube.
Position of electrode.
After a small incision on the surface of the anterior wall 
of the stomach, a platinum needle electrode was inserted from the 
serosa into the basal portion of the gastric mucosa. The 
electrode was positioned in a high blood flow area, between the 
two branches of the left gastric artery, closer to the lesser 
than the greater curvature of the corpus of the stomach as 
previously described (Raybould 1990; Tanaka 1993). The reference 
electrode (Ag-AgCl) was placed inside of the peritoneal cavity.
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Measurement of GMBF and Vascular Resistance.
After an equilibration period of 1 h, GMBF was measured by 
the hydrogen gas-clearance technique as described previously 
(Leung 1984). Each measurement involved a 30 min period 
including 15 min of saturation with 3% hydrogen gas and 15 min 
desaturation of the tissue. The gas clearance was analyzed by a 
computerized monoexponential direct curve-fitting program 
(Livingston 1989). Value of GMBF are expressed in ml/min/100 g. 
The mean arterial blood pressure (MAP) was recorded continuously 
throughout the duration of each experiment and expressed in mm 
Hg. Gastric mucosal vascular resistance (GMVR) was calculated by 
dividing the MAP taken at the beginning of the desaturation 
period by the respective blood flow and expressed in mm 
Hg/ml/min/100 g. The MAP time point was selected since the first 
minutes after the end of saturation period, the desaturation is 
rapid and has a maximal influence on the final curve fit 
measuring GMBF.
Experimental Protocols
Study 1. Effect of i.v. administration of CGRP receptor 
antagonist on i.v. a-CGRP-induced gastric hyperemia.
The inhibitory effect the CGRP antagonist, hCGRP8.37 against 
a-CGRP-induced increase in GMBF was first tested under our 
experimental conditions. GMBF was measured twice before and 
twice after starting the administration of vehicle (0.1% BSA 
containing 0.9% saline, i.v., n=5) or hCGRP^ (15 ng/kg i.v. 
bolus, followed by an infusion of 3 jig/kg/h throughout the 
experiment, n=5) . Then, both groups were infused with a-CGRP (14 
Mg/kg/h) into the splenic artery for a 30 min period during which 
GMBF was measured. The choice of the dose of a-CGRP was based on 
a previous study showing that close intra-arterial infusion of 
the peptide stimulates GMBF in urethane-anesthetized rats (Holzer 
1991a) . The dose of CGRP antagonist was based on preliminary
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Study 2. Effect of the CGRP receptor antagonist, hCGRP8_37, or 
substance-P antagonist, CP-96,345, given i.v. on intracistemal 
RX 77368-induced gastric hyperemia.
In the second experiment, GMBF was measured twice before and 
twice after hCGRP8.37 (14 /ig/kg, i.v. bolus injection followed by 
3 ptg/kg/h, n=6) or vehicle (0.1% BSA containing 0.9% NaCl, i.v., 
n=7) then, RX 77368 (30 ng) was injected intracisternally to both 
groups. Changes in GMBF were measured at 30 min intervals for 3 
h starting 5 min after TRH analog injection. In another group of 
rats, after two basal GMBF measurements, vehicle or the substance 
P receptor antagonist, CP-96,345 (3 mg/kg) was injected as a 
bolus. Five min íater vehicle or RX 77368 (30 ng) was injected 
intracisternally and after 5 min, the 30 min GMBF measurement was 
performed. The dose of CP-96,345 injected i.v. was based on 
previous studies showing the inhibition of substance P-induced 
salivation for over 90 min in rats (Plourde 1993; Snider 1991). 
The dose of TRH analog (30 ng) was selected based on previous 
studies showing a robust stimulation of GMBF under these 
conditions (Tanaka 1993) .
Study 3. Effect of capsaicin pretreatment on i.v. CGRP 
antagonist-induced inhibition of gastric hyperemic response to 
intracisternal RX 77368.
In capsaicin- or vehicle-pretreated rats, GMBF was measured 
twice before and twice after administration of vehicle or hCGRP8_37 
(15 M9/kg i.v. bolus, followed by an infusion of 3 jig/kg/h 
throughout the experiment). Then, RX 77368 (30 ng) was injected 
intracisternally to all groups (n=4 per group) and 5 min later, 
the 30 min period measurement of GMBF was performed over the 3 h 
experimental period.
Study 4. Influence of i.v. CGRP antagonist on bethanechol- 
induced gastric hyperemia.
GMBF was measured twice before and twice after the 
administration of vehicle or hCGRP8.J7 (15 ng/^g i.v. bolus, 
followed by an infusion of 3 /ig/kg/h throughout the experiment) ; 
then bethanechol chloride (150 /xg/kg/h) was infused close- 
arterially to both groups (n=4 per group) and GMBF was measured. 
The dose of bethanechol was selected to reproduce a similar 
increase in GMBF as that induced by intracisternal injection of 
TRH analog (30 ng).
Statistics
Results are expressed as means + SEM. Comparisons between 
two groups were calculated by Student's t-test, multiple group 
comparisons were performed by ANOVA followed by Duncan's 
contrast. P<0.05 was considered as statistically significant.
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3.2.1.3 Results
Study 1. Effect of i.v. administration of CGRP receptor 
antagonist on i.v. or-CGRP-induced gastric hyperemia.
Close intra-arterial infusion of or-CGRP (14 /ig/kg/h) for 30 
min increased significantly GMBF (ml/min/100 g) from basal level 
of 41.4 ± 4.4 to 72.9 ± 11.2 and decreased significantly MAP (mm 
Hg) and GMVR (mm Hg/ml/min/100 g) from 77 + 3 to 57 ± 6 and 1.9 
+ 0.2 to 0.8 + 0.1 respectively (Fig. 4A-C). Systemic infusion 
of hCGRPg.37 (15 ng/kg i.v. bolus followed by an infusion of 3 
(xg/k.g/h) did not influence vascular parameters and completely 
prevented the or-CGRP-induced elevation of GMBF and declines in 
MAP and GMVR (Fig. 4A-C).
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I ig. 4. Influence of the CGRP receptor antagonist. hCGRPt„  
on close in tra -arte ria l infusion of a-CGRP induced vascular changes in urethane-anostheti/ed rats. After 
two basal measurements. hCGRPg,7 (black coluivis) or vehicle (white columns) was injected intravenously 
( iv )  as a bolus ( IS  pg/kg or 0.3 ml) then as an intravenous infusion (3 pg/kg/h or 1.5 ml/h) throughout 
the experiment. a-CGRP (M pg/kg/h) was infused in tra -a rte ria lly  ( ia )  for 30 min to both groips.
starting at 60 min after the bolus injection fach coluwi represents the mean ± SIM of 5 rats. 
Measurements represent the 30-60 min period after the beginning of the infusion of vehicle or CGRP 
antagonist alone and the f i r s t  30 min period after a CGRP infusion with vehicle or CGRP antagonist. * 
P<0.01 compared with vehicle alone; + P<0.01 conpared with vehicle plus a-CGRP treated group.
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Study 2. Effect of the CGRP receptor antagonist, hCGRPg.37, 
or substance-P antagonist, CP-96,345, given i.v. on 
intracistemal RX 77368-induced gastric hyperemia.
Before treatment, the two experimental groups had similar 
basal GMBF (ml/min/100 g: 53.5 ± 3.6 and 55.3 ± 8.1), MAP (mm Hg: 
76 ± 3 and 77 ± 2) and GMVR (mm Hg/ml/min/100 g: 1.6 ± 0.2 and 
1.7 ± 0.2) (Fig. 5A-C) . Neither hCGRP8.37 nor vehicle 
administered for 1 h, influenced basal GMBF, MAP, and GMVR values 
(Fig. 5A-C). In the vehicle-pretreated group, intracistemal 
injection of RX 77368 (30 ng, i.c.) elevated GMBF, which reached 
a peak (123.6 +16.1 ml/min/100 g) during the first 30 min period 
post injection (Fig. 5A) . A significant elevation was still 
observed during the following 30 min period and thereafter values 
returned to the basal levels (Fig. 5A) . hCGRPg.37 infusion 
abolished RX 77368-induced increase in GMBF (Fig. 5A) . In 
vehicle- or hCGRPg_37-infused groups, intracistemal injection of 
RX 77368 elevated MAP values that reached 116 + 6 mm Hg and 127 
+ 4 mm Hg respectively. Thereafter, MAP values declined similarly 
in both groups to return to basal levels at the third 30 min 
period after TRH analog injection (Fig. 5B) . Intracistemal 
injection of RX 77368 decreased GMVR in vehicle-treated animals 
and increased GMVR in the CGRP antagonist-treated group during 
the first two 30 min period after TRH analog injection (Fig. 5C). 
No gastric erosions were observed by visual inspection after 
intracistemal injection of RX 77368 under these conditions.
Intravenous injection of the substance P receptor 
antagonist, CP-96,345 (3 mg/kg), modified neither the basal GMBF, 
MAP and GMVR levels nor RX 77368-induced rises of GMBF and MAP 
and reduction of GMVR (Table 1).
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r iq . 6. Influence of Uie CGRP receptor antagonist. hCORP,,7 (16 pg/kg bolus + 3 pg/kg/h ív. black 
columns) or vehicle (0.3 ml + 1 . 6  ml/h. ív. white coluiris) on RX //368-induced stimulation of gastric  
mucosal blood flow ( A ) .  mean arte ria l pressure (B) and ga stric  mucosal vascular resistance (C) in 
urethane-anestheti/ed rats, fach col hit represents the mean + SfH of 6 - 7  rats/grxxp. * P<0.05 compared 
with respective basal values: + P<0.06 compared with vehicle plus RX 77368-treated group
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Table 1. Effect of the substance P antagonist, CP-96,345, on intracisternal TRH analog-induced increases 
in gastric oucosal blood flow (GH8P) in urethane-anesthetized rats.
Treatment* N GMBFb MAPb GMVRb
(ml/min/100 g) (mm Hg) (mmHg/ml/min/100 g)
Basal 12 55.3±8.1 77+ 8 1.4±0.4
Veh.+Veh. 4 51.3±8.1 76±5 1 .5±0.1
CP-96,345 + 4 51.9±3.6 78±6 1 .5±0.2
Vehicle *
CP-96,345 + 4 128.0±24.0* 106±7* 0 .8±0.1*
RX 77368
* After a basal GMBF measurement, vehicle or CP-96,345 was 
injected (3 mg/kg, i.v.), then 5 min later, vehicle or TRH 
analog, RX 77368 (30 ng) was given intracisternally. GMBF 
measurement was performed during the next 30 min period. MAP was 
monitored through the femoral artery at 15 min before injection 
of vehicle or CP-96,345 (basal), and 15 min after intracisternal 
injection.
b Mean ± SEM of number of rats listed as N, * P<0.05 compared with 
basal values.
Study 3. Effect of capsaicin pretreatment on i.v. CGRP 
antagonist-induced inhibition of gastric hyperemic response to 
intracistemal RX 77368.
Sensory nerve ablation by systemic capsaicin pretreatment 
did not alter the basal GMBF (58.3 ± 5.8 ml/min/100 g), MAP (84 
+ 2 mm Hg), and GMVR (1.4 + 0.1 mm Hg/ml/min/100 g) (Fig. 6A-C) 
compared with vehicle-pretreated rats (GMBF: 55.3 ± 7.9 
ml/min/100 g; MAP: 80 ± 8 mm Hg, GMVR: 1.4 + 0.2 mm Hg/ml/min/100 
g) (Fig. 5A-C) . Intravenous administration of hCGRP8.37 did not 
modify basal GMBF, MAP and GMVR values in both vehicle- or 
capsaicin-pretreated rats (Fig. 6A-C). The CGRP antagonist, 
hCGRPg.37 completely prevented the rise of GMBF induced by RX 
77368 in vehicle-pretreated rats (Fig. 6A) as observed in non 
vehicle-pretreated' rats (Fig. 5A) . However, intravenous 
administration of hCGRP8.37 failed to reverse the gastric 
hyperemic response to RX 77368 (30 ng, i.c.) in capsaicinized 
rats (Fig. 6A) . In capsaicin-pretreated rats, the elevation of 
GMBF observed during the first 30 min period after RX 77368 
injection reached its peak: 135.5 ± 18.6 ml/min/100 g, then 
values decreased to basal level within 90 min after the 
injection. The magnitude and duration of the gastric hyperemic 
response to intracistemal injection of RX 77368 in capsaicin- 
pretreated rats were similar to those observed in non pretreated 
rats (Figs. 5A and 6A ) . RX-77368 induced a similar rise in MAP 
in vehicle- and capsaicin-pretreated rats infused either with 
vehicle or the CGRP antagonist (Fig. 6B) . hCGRP8.37 did not block 
the decrease in GMVR induced by RX 77368 in capsaicin-pretreated 
rats (Fig. 6 0  .
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r ig . 6. Influence of CGRP receptor antagonist. hCGRP,,, (15 //g/kg + 3 pg/kg/h. iv ) on intracistem al 
injection of RX 77368-induced stimulation of gastric  mucosal blood flow (A), mean a rte ria l pressure (B) 
and gastric  mucosal vascular resistance (C) in capsaicin- (s tr ip  or black coluins) or vehicle- pretreated 
(white coluwis). urethane-anesthetized rats Iach co lim  represents mean ± SIM of 4 rats/group. * P<0.05 
compared with respective basal values: ♦  P<0.05 compared with vehicle-pretrealed group.
Study 4. Influence of i.v. CGRP antagonist on bethanechol- 
induced gastric hyperemia.
Close intra-arterial infusion of bethanechol (150 (ig/kg/h) 
enhanced the basal GMBF from 52.4 ± 5.1 ml/min/100 g to 106 ± 
15.8 ml/min/100 g (Fig. 7A) with a parallel decrease in GMVR from 
1.7 + 0.2 to 0.7 ± 0.1 mm Hg/ml/min/100 g during the first 30 
min period of infusion (Fig. 7C) . Systemic administration of 
hCGRPg.37 under the same conditions as in previous studies 1-3 
inhibited the vascular responses to bethanechol (GMBF: 67.7 ± 8.7 
ml/min/100 g, GMVR: 1.4 + 0.2 mm Hg/ml/min/100 g) . The MAP was 
not altered by close arterial infusion of bethanechol in vehicle- 
or CGRP antagonist-pretreated rats (Fig. 7B).
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Tig. 7. Influence of CGRP receptor antagonist. hCGRP837 (IS  /xj/kg *  3 j/g/kg/h. iv ) on close arterial 
infusion of bethanechol-induced (ISO j/g/kg/h, ia) stimulation of gastric  mucosal blood flow (A), mean 
arterial pressure (B) and gastric  mucosal vascular resistance (C) in urethane-anestheti/ed rats. HAP was 
monitored through the femoral artery at 15 min before (basal) and 15 min after i.v .  administration of 
drugs. Tach colum represents the mean ± SfH of A rats/groep. * P<0.05 compared with respective basal 
values: + P<0.05 compared with vehicle plus bethanechol-treated group.
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3.2.1.4 Discussion
Intracisternal injection of the stable TRH analog, RX 77368 
at 30 ng increased the GMBF by 131% during the first 30 min 
period after the injection as measured by the hydrogen gas 
clearance technique in urethane-anesthetized rats. Thereafter, 
GMBF values are decreasing to reach basal levels within 90 min 
after peptide injection. Likewise, previous reports indicate that 
RX 77368 injected into the cisterna magna at 30 ng or TRH 
injected into the lateral ventricle or dorsal vagal complex 
induced a robust increase in GMBF assessed by the hydrogen gas- 
or aminopyrine-clearance technique (Okuma 1987; Thiefin 1989; 
Raybould 1990; Tanaka 1993) .
Convergent evidence demonstrated that the gastric hyperemic 
response to central injection of TRH or RX 77368 is mediated by 
vagal efferent cholinergic pathways.
First, the increase in GMBF can be reproduced by direct 
microinjection of TRH into the dorsal motor nucleus of the vagus 
(Okuma 1987) .
Second, injection of TRH or RX 77368 into the CSF 
stimulates efferent activity recorded in the cervical or the 
gastric branch of the vagus (Somiya 1984; Mattila 1986).
Third, vagotomy completely abolished the rise in GMBF 
induced by TRH injected centrally (Thiefin 1989).
Fourth, in the present study, the muscarinic agonist, 
bethanechol, infused close intra-arterially to the stomach at a 
dose which did not influence systemic blood pressure, elevates 
GMBF by 102% but decreases vascular resistance by 41%.
Fifth, peripheral but not central injection of the 
muscarinic antagonist, atropine, completely suppressed the 
increase in GMBF induced by central injection of TRH (Okuma 1987; 
Thiefin 1989).
Our previous studies indicate that RX 77368 injected 
intracisternally at 30 ng induced a maximal acid secretory 
response 30 min post injection in urethane-anesthetized rats 
(Raybould 1990; Tanaka 1993). However, the rise in GMBF induced
by TRH injected into the CSF is not secondary to vagal 
cholinergic stimulation of acid secretion since the hyperemic 
response was maintained in omeprazole-treated rats (Thiefin 
1989) . The increase in GMBF and decrease in gastric vascular 
resistance is also not related to the alterations in MAP. 
Injection of TRH or RX 77368 into the CSF increased MAP (Forster 
1993b) and present observation which is indicative of an increase 
in total systemic vascular resistance, while in the gastric 
submucosa, vascular resistance was found to be decreased (Tanaka 
1993), present observation. Convergent electrophysiologic and 
functional evidence have established that the increase in MAP and 
heart rate induced by TRH injected into the CSF results solely 
from sympathetic hyperactivity. By contrast, the gastric mucosal 
hyperemia originates mainly from activation of vagal cholinergic 
pathways (Mattila 1986; Thiefin 1989). These data along with the 
existing knowledge on the organization of the gastric 
microcirculation (Guth 1987) indicate that the increase in GMBF 
must result from vagal muscarinic mediated vasodilation occurring 
locally in the gastric submucosal arterioles.
Several peptide exert a vasodilatory effect, however CGRP 
was established to be one of the most potent vasodilators of 
blood vessels in the gastric mucosa and submucosa as well as in 
other vascular beds. The peptide affects only resistance 
(arteries and arterioles) and not capacitance vessels (veins and 
venules) (Brain 1985; Holzer 1991a; Chen 1992). In the present 
study, two specific observations indicate that CGRP participates 
in the rise in GMBF induced by intracisternal injection of RX 
77368 in intact rats.
First, consistent with several previous studies, a-CGRP 
infused intra-arterially close to the stomach increased GMBF 
while the vascular resistance and MAP were lowered in urethane- 
anesthetized rats (Holzer 1991a; Chen 1992). The enhanced GMBF 
despite reduced perfusion pressure reflects effective dilation of 
gastric mucosal blood vessels in agreement with previous findings 
(Holzer 1991a) . The use of in vivo microscopy and topical
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application of o'-CGRP on gastric submucosal arterioles further 
confirmed that or-CGRP exerts a direct vasodilatatory action on 
gastric submucosal arterioles involving interaction with CGRP-1 
receptor subtype (Chen 1992). Likewise, in the present study, 
the systemic and gastric vascular effects of close intra-arterial 
infusion of o'-CGRP were completely prevented by intravenous 
infusion of the CGRP-l receptor antagonist, hCGRP8.37. The CGRP-1 
receptor mediated vasodilatory effect of o'-CGRP is well 
correlated with the dense representation of of-CGRP binding sites 
in the arteries and arterioles of the gastric submucosa (Gates 
1989) .
Second, when hCGRP8.37 was infused at a dose blocking the 
gastric hyperemic response to exogenous o'-CGRP and having no 
effect on basal 'GMBF, the 131% rise in GMBF induced by 
intracisternal injection of the TRH analog was completely 
inhibited. Likewise, the CGRP antagonist reduced by 73% the 
similar increase in GMBF induced by bethanechol infused close 
intra-arterially to the stomach. Topical application of 
bethanechol was reported previously to induce an atropine- 
sensitive dilatation of gastric submucosal arterioles (Morishita 
1986) . The decrease in vascular resistance induced by 
intracisternal injection of RX 77368 and by close arterial 
infusion of bethanechol was also counteracted by the infusion of 
hCGRPg.37. By contrast, the rise in MAP induced by central TRH 
analog was not altered by the CGRP antagonist. These data further 
show that intracisternal injection of the TRH analog increases 
GMBF independently from changes in systemic blood pressure. CGRP 
was previously reported to play a major role in the gastric 
hyperemic response induced by acute exposure of the mucosa to 
capsaicin and acid back diffusion (Li 1991; Li 1992). However, 
the present findings provide the first evidence to suggest that 
CGRP participates in the peripheral mechanisms responsible for 
the gastric hyperemia induced by central vagal cholinergic 
activation.
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Immunohistochemical studies demonstrate that a-CGRP in the 
rat stomach is contained almost exclusively in unmyelinated 
capsaicin-sensitive afferent neurons originating mainly from the 
dorsal root ganglia (Raybould 1992; Sternini, 1992). Systemic 
capsaicin pretreatment ablates the dense CGRP immunoreactivity 
contained in splanchnic neurons around blood vessels in the 
gastric mucosa (Raybould 1992; Sternini, 1992). In addition, 
functional evidence indicates that capsaicin-sensitive sensory 
neurons play an important role in the regulation of GMBF mainly 
through the local release of CGRP from peripheral terminals 
(Holzer, 1988; Chen 1992; Raybould 1992). In the present study, 
hCGRP8.37 no longer inhibits the 157% increase in GMBF induced by 
intracisternal injection of RX 77368 in capsaicin-pretreated 
rats. By contrast, in animals pretreated with vehicle, the CGRP 
antagonist blocked the rise in GMBF as observed in non pretreated 
rats. These findings indicate that hCGRP8.37 antagonizes the 
biological action of CGRP originating primarily from capsaicin- 
sensitive afferents. These data suggest that in intact rats 
central vagal activation induces CGRP released from capsaicin- 
sensitive afferent terminals which exerts a local "efferent" 
function on GMBF (Holzer, 1988) .
Increase in GMBF is one of the major mechanism through which 
capsaicin-sensitive afferents mediate the prevention of gastric 
mucosal injury induced by ethanol (Holzer 1991b). We previously 
reported that intracisternal TRH or RX 77368 at low doses induced 
protection against ethanol-induced gastric lesions (Yoneda 1992; 
Yoneda 1993b; Király 1993). Such gastric cytoprotective action of 
central TRH was also shown to involve CGRP recruited from 
capsaicin-sensitive sensory neurons (Kato 1994). The present 
observations may have implications to the understanding of CGRP 
dependent mechanisms mediating the gastric cytoprotection induced 
by intracisternal injection of TRH analog.
Although the small mesenteric arterioles of the submucosa of 
the stomach are densely innervated by CGRP containing fibers
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(Sternini, 1992), substance P is also present to a lesser extent 
in capsaicin-sensitive spinal afferent fibers (Sharley 1984). 
However, previous studies indicate that substance P does not 
stimulate GMBF (Gepetti 1991; Holzer 1991a; Gronbech 1994). 
Likewise, in the present study, injection of CP-96,345 a 
selective substance P antagonist, at the neurokinin-1 receptor 
subtypes (Snider 1991) was ineffective in altering the GMBF in 
response to intracisternal injection of the TRH analog. The 
antagonist was given at a dose established to prevent the actions 
of substance P in other biological systems (Snider 1991; Plourde 
1993). These data further demonstrated the specificity of CGRP 
antagonist action on the gastric hyperemic response to RX 77368 
injected intracisternally.
The mechanisms through which the stimulation of central 
vagal muscarinic efferent pathways activate the local "effector" 
functions of C-terminal capsaicin-sensitive neurons containing 
CGRP (Holzer, 1988) remain to be investigated. Acid back 
diffusion-induced gastric mucosal hyperemia is mediated by CGRP 
release from capsaicin- sensitive fibers (Gepetti 1991; Li 1992) . 
Gastric acid secreted in response to injection of RX 77368 was 
removed from the stomach by continuous perfusion with 0.9% NaCl, 
pH=7. In addition intracisternal injection of TRH analog at the 
30 ng dose not induce gastric mucosal lesions within 30 min. 
Therefore it is unlikely that the activation of CGRP release from 
capsaicin-sensitive afferent fibers is secondary to changes in 
gastric acid secretion or mucosal integrity. Possible 
mechanisms may involve a direct excitatory action of 
acetylcholine on peripheral nociceptive C-fibers as recently 
demonstrated in the vasodilatory response to acetylcholine in the 
rat skin microvasculature (Ralevic 1992) . We previously 
demonstrated that intracisternal injection of RX 77368 induced a 
vagal cholinergic mediated release of PGE2 (Yoneda 1993b), 
histamine (Yanagisawa 1990a), and serotonin (Stephens 1989; Yang 
1992). Prostaglandins and serotonin have been shown to sensitize
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the majority of the C-polymodal afferents and to activate 
capsaicin-sensitive afferent C-fibers leading to the release of 
CGRP in the rat trachea and lungs (Lundberg 1992; Hua 1993). 
Furthermore histamine, and serotonin were reported to sensitize 
and/or to excite certain limited populations of capsaicin- 
sensitive polymodal C-fiber afferents in the lung, or stomach 
(Lundberg 1992; Hua 1993). It can be hypothesized that these 
agents activate sensory C-fibers that lead to the release of CGRP 
in the gastric mucosa.
Vagal cholinergic release of nitric oxide was recently 
reported to be involved in mediating the gastric hyperemic and 
cytoprotective effects induced by intracisternal injection of TRH 
analog (Tanaka 1993) . The involvement of nitric-oxide dependent 
pathways may be related to a-CGRP receptor activation. Nitric 
oxide is the major secondary mediator of the gastric hyperemic 
and protective actions of CGRP released from sensory nerve 
endings in the stomach (Holzer 1993; Lambrecht 1993). The 
complete abolition of the gastric hyperemic response to 
intracisternal injection of RX 77368 at 30 ng by either the CGRP 
antagonist (present observation) or by the nitric oxide synthase 
inhibitor, L-NAME, (Tanaka 1993) is compatible with such a CGRP- 
dependent nitric oxide activation resulting in gastric 
vasodilation in intact animals.
In capsaicin-pretreated rats in which gastric sensory 
afferents containing CGRP are ablated, intracisternal injection 
of RX 77368 still increased GMBF with a similar magnitude as in 
vehicle-pretreated rats. Further studies indicate that the 
nitric oxide synthase inhibitor, L-NAME, abolished intracisternal 
RX 77368 (30 ng)-induced rise in GMBF in capsaicin-pretreated 
rats (Király 1997b). In addition, L-NAME action was reversed by 
L- but not by D-arginine (Király 1997b). These findings suggest 
that in capsaicin-pretreated rats, nitric oxide increases GMBF 
through vagal efferent cholinergic mechanisms independently from 
CGRP pathways as demonstrated in the skin vasculature (Ralevic
1992) .
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In summary, these findings suggest that in capsaicin-treated 
rat, central vagal activation induced by TRH analog increases 
GMBF by CGRP independent mechanisms. By contrast, in intact rats, 
the gastric hyperemia induced by intracisternal injection of TRH 
analog at 30 ng dose involves vagal cholinergic activation of the 
local "effector function" of capsaicin-sensitive fibers releasing 
the vasodilatory peptide CGRP. These data provide evidence that 
upon central vagal activation, there is an interaction between 
vagal efferent cholinergic pathways and sensory afferent fibers 
containing CGRP. Such cross talk may have functional 
implications as activated capsaicin sensory afferents may 
generate local as well as central reflex modulating gastric 
response to vagal efferent stimulation.
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3.2.2 Peripheral mediators involved in gastric hyperemic 
response to vagal activation by central TRH analog in rats
3.2.2.1 Background
Central injection of TRH or TRH analogs stimulate gastric vagal 
efferent discharges (Somiya 1984; 0-Lee 1997) and
gastrointestinal secretory and motor functions and modulate the 
resistance of the gastric mucosa to injury through vagal atropine 
sensitive pathways (Tache 1988; Tache 1994a) . Central TRH also
stimulates exocrine pancreatic and duodenal bicarbonate secretion 
and net ileal and jejunal water secretion through vagal atropine- 
sensitive as well 'as insensitive pathways (Lenz 1989; Messner 
1993; Lenz 1995) . The physiological role of medullary TRH was 
further established by the demonstration that TRH antibody 
microinjected into the cisterna magna or DMN abolished the 
vagally mediated adaptive gastric protection, and gastric 
responses to cold exposure, 2-deoxy-D-glucose and chemical 
activation of midline raphe cell bodies (Yang 1993; Kaneko 1995a; 
Kaneko 1995b; Okumura 1995).
The mechanisms involved in the vagal regulation of gastric 
mucosal blood flow (GMBF) were previously investigated using 
electrical stimulation of the vagus nerve (Guth 1975; Guth 1987) . 
The associated stimulation of gastric acid secretion was 
originally postulated to account for the gastric hyperemic 
response (Guth 1987). However, in vivo microscopy techniques 
provided evidence for a direct vasodilatory effect on gastric 
submucosal arterioles mediated by atropine-sensitive 
(cholinergic) and atropine resistant mechanisms particularly at 
high frequencies of vagal stimulation (Guth 1987; Thiefin 1990). 
Since electrical activation of the vagal nerve trunk can produce 
orthodromic as well as antidromic activation of vagal fibers 
(Thiefin 1990), injection into the cerebrospinal fluid of TRH or 
the stable analog, RX 77368 provides a more relevant
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physiological tool to gain insight into the peripheral mechanisms 
underlying changes in GMBF induced by vagal efferent activation 
(Thiefin 1989; Tanaka 1993; Király 1994).
In earlier studies, we have shown that central injection of 
TRH or RX 77368 increased GMBF independently from the stimulation 
of gastric acid secretion and prostaglandin generation in 
urethan-anesthetized rats (Thiefin 1989; Tanaka 1993; Tanaka 
1997). In particular, RX 77368 injected ic at 1.5 ng activated 
gastric vagal efferent discharge (0-Lee 1997) and increased GMBF 
while being subthreshold to stimulate gastric acid secretion 
(Yoneda 1993b; Király 1997b). The hyperemic response under these 
conditions was primarily mediated by an "efferent function" of 
capsaicin-sensitive primary afferent fibers containing calcitonin 
gene-related pepticle (CGRP) (Király 1997b) . By contrast, when RX 
77368 was injected at 30 ng, leading to a robust stimulation of 
gastric vagal efferent activity and acid secretion (Tanaka 1993; 
0-Lee 1997), the increase in GMBF was not altered by capsaicin (- 
10 days) alone or in combination with intravenous injection of 
CGRP antagonist or omeprazole at a dose blocking the stimulated 
acid secretion (Király 1994; Tanaka 1997). The vasodilator 
transmitters involved under conditions of sustained central vagal 
efferent stimulation in capsaicin-pretreated rats have not yet 
been identified. Therefore, the present study was undertaken to 
explore the mediators participating in the regulation of GMBF 
after ic injection of RX 77368 at 30 ng in urethan-anesthetized 
rats. We determined whether gastric hyperemia is muscarinic in 
nature or whether additional, atropine resistant, mechanisms also 
participate, as observed with electrical vagal stimulation at 
high frequency (Guth 1987; Thiefin 1990). Secondly, we 
investigated whether the atropine-dependent response is mediated 
by histamine, and/or nitric oxide (NO) using the histamine 
receptor antagonist (H,-) , pyrilamine, and L-NMMA (N°-nitro- 
monomethyl-L-arginine), a NO synthase inhibitor which is devoid 
of direct muscarinic antagonist properties (Buxton 1993). These
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Substances are potential candidates as they are released or 
generated through vagal muscarinic dependent mechanisms in the 
gastric effluent after ic injection of RX 77368 at 30 ng 
(Yanagisawa 1990a; Yoneda 1993b; Saperas 1995) and have 
vasodilatory properties in the gastric mucosa (Guth, 1991; Guth 
1987; Whittle, 1993) . We also investigated whether the GMBF 
response maintained in capsaicin-pretreated rats after ic 
injection of RX 77368 at 30 ng (Király 1994) is sensitive to NO 
synthase inhibition. Lastly, in view of the report that 
intravenous injection of L-NAME inhibits NO synthase activity in 
the rat forebrain (iadecola 1994), we also compared the effects 
of peripheral (iv) vs central (ic) injection of L-NAME (N°-nitro- 
L-arginine-methylester) to ascertain the peripheral action of NO 
inhibitors.
3.2.2.2 Materials and methods
Drugs
The following substances were used: the stable TRH analog, 
RX 77368 (p-Glu-His-(3,3'-dimethyl)-Pro-NH2) (Reckitt & Colman, 
Kingston-upon-Hill, England), atropine sulfate, capsaicin, 
pyrilamine, L-NAME (NG-nitro-L-arginine-methylester), L-NMMA (Nc- 
nitro-monomethyl-L-arginine), L-arginine hydrochloride and D- 
arginine hydrochloride, all from Sigma Chemical Co. (St. Louis, 
MO). RX 77368 was aliquoted in 0.1% bovine serum albumin (BSA) 
and 0.9% saline at a concentration of 3 ptg/10 n 1, and kept frozen 
at -70 °C. The stock solution of RX 77368, and atropine sulphate, 
pyrilamine, L-NAME, and L-NMMA in powder form were dissolved in
0.9% saline (PH=7.0) before administration. Capsaicin was 
dissolved in vehicle (absolute ethanol, Tween 80 and isotonic 
saline, 10:10:80:v/v/v). Unless otherwise stated, the volume for 
ip, sc, and iv bolus injections was 0.3 ml and iv infusion was 
1.5 ml/h.
Király, 56
Animal Preparations and Surgical Procedures
All the surgical procedures performed for simultaneous 
measurements of GMBF and mean arterial blood pressure (MAP) and 
for drug administration were essentially as previously described 
in chapter 3.2.
Experimental Protocols
In all experiments, after one or two basal GMBF
measurements, pretreatment was given and, at different time 
intervals thereafter, the TRH analog was injected ic at 30 ng. 
GMBF and MAP measurements were performed at various time 
intervals before and after ic injection. When pretreatments were 
injected ip or sc, saline 1.5 ml/h was infused to maintain 
hydration.
Study 1. Effect of atropine, and pyrilamine.
In the first series of experiments, after basal GMBF and MAP 
measurements, rats received vehicle (0.9% saline, sc) or atropine 
sulfate (2 mg/kg, sc); pyrilamine (1 mg/kg iv bolus followed by 
2 mg/kg/h, iv infusion) or vehicle (0.9% saline, 0.3 ml iv bolus 
followed by 1 .5 ml/h iv infusion). Thirty min after atropine and 
60 min after pyrilamine, RX 77368 (30 ng) was injected ic and
GMBF, MAP and GMVR were monitored before and up to 120 min after 
RX 77368 injection.
Study 2. Effect of capsaicin, L-NMMA and L-NAME.
After basal measurements, L-NMMA (50 mg/kg, iv) or vehicle 
(0.9% saline, iv) was administered and 15 min later, RX 77368 (30 
ng) was injected ic. The selection of L-NMMA dose was based on an 
equal rise in blood pressure as L-NAME (Rees 1990). In a second 
set of studies, rats were injected sc with capsaicin (25, 50 and 
50 mg/kg in 0.5 ml) at 12-h intervals. The first capsaicin 
injection was performed under short enflurane anesthesia. After 
10-14 days, capsaicin-pretreated rats showed the disappearance of 
the corneal chemosensory reflex (eye wiping for 1-3 min to a drop
of 0.1% NH4OH instillated into each eye when tested just before 
the experiment). After basal GMBF measurements, capsaicin- 
pretreated rats were injected iv with vehicle (saline), L-NAME 
(10 mg/kg), L-NAME (10 mg/kg) plus L-arginine (500 mg/kg) or L- 
NAME (10 mg/kg) plus D-arginine (500 mg/kg) and 15 min later, RX 
77368 (30 ng) was injected ic. GMBF, MAP and GMVR were measured 
before and after ic injection of RX 77368 (30 ng). In the third 
set of experiments, after basal measurements, L-NAME (500 /xg/kg, 
ic) or vehicle (saline, ic) was injected 15 min before RX 77368 
(30 ng, ic) or vehicle (saline). Each substance was injected ic 
in a 5 /il volume followed by 5 /xl flush of the catheter with 
saline (total volume: 20 nl) . The changes in GMBF, MAP and GMVR 
were monitored before and after RX 77368.
Statistics
Results are expressed as means ± SEM. Comparisons between 
two groups were calculated by Student's t-test. Comparisons 
before and after treatment were analyzed by Student's paired t- 
test. Multiple group comparisons were performed by ANOVA followed 
by Duncan's contrast. P<0.05 was considered statistically 
significant.
3.2.2.3 Results
Study 1. Effect of atropine and pyrilamine on GMBF, MAP and GMVR 
Changes Induced by Intracistemal RX 77368 at 30 ng
The basal GMBF was 54.2 ± 8.0 ml/min/100 g (Fig. 8A) , MAP
80.4 ± 6.9 mmHg (Fig. 8B), and vascular resistance, 1.6 ± 0.3 mm 
Hg/ml/min/100 g (Fig. 8C) in urethan-anesthetized rats. GMBF, MAP 
and GMVR remained stable when measured again at a 30 min interval 
and following sc injection of either vehicle or atropine (Fig. 
8A-C). In the vehicle-injected group, RX 77368 (30 ng, ic) evoked 
a peak increase in GMBF during the first period measurement after 
peptide injection reaching 138.9 ± 16.2 ml/min/100 g which
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represents a 157% increase from pre-injection levels (Fig. 8A). 
Blood pressure also significantly increased to 116 + 3 mm Hg at 
15 min after ic injection of TRH while GMVR significantly 
decreased to 0.9 + 0.1 mmHg/ml/min/lOO g (Fig. 8B,C). Thereafter, 
changes in GMBF, MAP and GMVR declined and reached preinjection 
basal values at 75 min post injection (Fig. 8) . Atropine (2 
ntg/kg, sc, -30 min) completely abolished RX 77368 (30 ng, ic) - 
induced stimulation of GMBF and decrease in GMVR while the rise 
in MAP was not significantly modified (Fig. 8) . Pyrilamine 
infusion (1 mg/kg bolus + 2 mg/kg/h, iv) influenced neither the 
basal nor RX 77368-induced increase in GMBF and MAP and decrease 
in GMVR (Table 2).
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Fig. 8. Influence of atropine (? mg/kg. sc) on RX 77368-induced changes in gastric  mucosal blood flow 
(GMBF). mean arte ria l pressure (M4P) and gastric  mucosal vascular resistance (CHVR) in urethan- 
aneslheti/ed rats. Fach colimti represents mean ± SFM of 4-5 rats7group. * P< 0.05 compared with 
respective basal values: + P< 0.05 ecmpared with vehicle plus RX 77368-treated group.
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Table 2. Effect of pyrilanine on intracisternal RX 77368-induced changes of GHBF, HAP and GHVR in
urethane-anesthetized rats
Treatments* N GMBF
(ml/min/100 g) ^
MAP
(mmHg) *
GMVR
(mmHg/ml/inln/lOO g)b
Basal 11 51.0±3.0 78±3 1.6±0.1
Vehicle 7 48.7±3.5 76±5 1.6±0.2
Vehicle + 
RX 77368
7 123.5±16.1* 114±3* 0.9±0.1*
Pyrilamine 4 50.8±8.0 82±3 1.7+0.3
Pyrilamine 
+ RX 77368
4 125.4±33.2* 118±6* 0 .9±0.4*
* After basal measurements, vehicle (0.3 ml + 1.5 ml/h, iv), or 
pyrilamine (1 mg/kg bolus + 2 mg/kg/h iv) was injected. After an 
additional 45 min, GMBF, MAP and GMVR were measured and 15 min 
later, RX 77368 (30 ng, ic) was injected. Measurement was
performed during the next 15-30 min period.
b Mean ± SEM of number of rats shown in column n. *: P< 0.05 
compared with basal.
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Study 2. Effect of L-NMMA, capsaicin alone or with L-NAME
Intravenous injection of L-NMMA (50 mg/kg) completely 
abolished the increase in GMBF elicited by ic injection of RX 
77368 (30 ng) (Fig. 9A). The rise in blood pressure induced by ic 
injection of RX 77368 was further enhanced by L-NMMA in magnitude 
(+20 mmHg) and duration (105 min instead of 75 min to reach basal 
level) (Fig. 9B). Vascular resistance which was decreased by ic 
RX 77368 in vehicle-treated rats was enhanced in the presence of 
L-NMMA compared with preinjection values for the 75 min period 
post injection (Fig. 9 0  .
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represents mean ± SIM of 4-9 rats/group. * P< 0 OS compared with respective basal values: + P< 0.05
conpared with vehicle plus RX 77368 treated
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In capsaicin-pretreated rats, ic injection of RX 77368 (30 
ng) induced a peak in the increase of GMBF (ml/min/lOO g) from 
58.2 + 2.9 to 149.5 ±9.5 and decreased GMVR during the 15-30 min 
post injection, then values returned to preinjection levels (Fig. 
10A,C). Pretreatment with L-NAME (10 mg/kg, -15 min) completely 
abolished the increase in GMBF and decrease in GMVR induced by RX 
77368 (Fig. 10A,C). L-arginine (500 mg/kg) injected iv before L- 
NAME restored the increase in GMBF and decrease in GMVR induced 
by ic TRH analog. However, under the same conditions of iv 
administration, the stereoisomer, D-arginine (500 mg/kg), failed 
to reverse the inhibitory effect of L-NAME on gastric vascular 
changes induced by ic TRH analog (Fig. 10A,C). In L-NAME or L- 
NAME plus D-arginirie treated groups, injected ic with RX 77368, 
GMVR was increased compared with respective pre-injection values 
(Fig. 10C). The rise in MAP induced by ic injection of RX 77368 
in capsaicin-pretreated rats was further enhanced by L-NAME in 
magnitude (+ 27 mrnHg) and duration (over 105 min) (Fig. 10B). L- 
arginine, unlike D- arginine, reversed the amplifying effect of 
L-NAME on blood pressure while not influencing the rise induced 
by ic RX 77368 (Fig. 10B).
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F ig . 10. Influence of NG-nitro-l-arginine methyl ester (I - NAHT) alone (10 mg/kg. iv. black columns) or 
combined by I-o r  D-arginine (600 mg/kg. iv. scattered or stripped colum s. respectively) on RX 77368- 
induced changes in gastric  mucosal blood flow (GMRf). mean arte ria l pressure (MAP) and gastric  mucosal 
vascular resistance (GMVR) in urethan-anesthetized rats pretreated with capsaicin. Fach column represents 
mean ± SFM of 4-9 rats/groip. * P< 0.05 compared with respective basal values: + P< 0.05 compared with
vehicle plus RX 77368-treated
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L NAME (500 M9/kg) injected into the cisterna magna did not 
alter ic injection of TRH analog (30 ng) induced changes in GMBF, 
GMVR and MAP (Table 3) . l -n a m e injected ic alone did not 
influence basal GMBF but increased MAP and GMVR (Table 3).
Table 3. Bffeet of ic injection of L-NAMR on ic RX 77368-induced changes in GMBF, HAP, GMVR in urethan-
anesthetized rats
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Treatments* N GMBF MAP GMVR
(ml/min/100 g)*> (mm Hg)k (mm Hg/ml/lOO g)b
Basal 20 49.0±2.9 8i±3 1.7±0.1
Veh. + Veh. 4 50.8±6.4 77±6 1.6±0.2
Vehicle + 4 123.0±15.2* 114±3* 1.0±0.2*
RX 77368
L-NAME + 4 52.5±1.4 117±5* 2.2+0.2*
Vehicle
L-NAME + 8 ' 114.7±9.9* 114±5* 1.1±0.1*
RX 77368
"After basal GMBF and GMVR measurements, vehicle (5 jzl, ic) or 
L-NAME (500 jig/kg, ic) was injected. Fifteen min later, vehicle 
or RX 77368 (30 ng, ic) was injected and GMBF and GMVR 
measurements were performed during the next 30 min period. MAP 
was monitored through the femoral artery, 30 min before (basal) 
the beginning of ic injections and 15 min after the 
administration of RX 77368.
bMean + SEM of number of rats indicated in column N. *: P< 0.05 
compared with vehicle + vehicle group.
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3.2.2.4 Discussion
The stable TRH analog, RX 77368 injected ic at 30 ng 
increased GMBF as shown by the hydrogen gas clearance technique 
in urethan-anesthetized rats. These results are consistent with 
previous studies using intracerebroventricular injection of TRH 
at 1-5 ng or intracisternal administration of RX 77368 at a 
similar or lower dose (1.5 ng) and monitoring the increase in 
GMBF by either the aminopyrine clearance, laser Doppler or 
hydrogen gas clearance techniques (Thiefin 1989; Tanaka 1993; 
Király 1994; Tanaka 1997). The gastric hyperemic response to 
central TRH or RX 77368 is mediated by vagal dependent 
pathways.
First, injection of TRH (3-300 ng) or RX 77368 (1.5-15 ng) 
resulted in a 90-145% and 140-244% increase in the gastric 
vagal efferent discharges respectively in urethan-anesthetized 
rats (0-Lee 1997).
Second, selective microinjection of TRH into the dorsal 
motor nucleus of the vagus mimicked the effect of peptide 
injection into the cerebrospinal fluid (Okuma 1987).
Third, vagotomy completely abolished the increase in GMBF 
evoked by TRH injected intracerebroventricularly (Thiefin 
1989) .
Convergent sets of evidence in rats indicate that central 
vagal activation-induced an increase in GMBF through an 
atropine-sensitive mechanism. In the present study, atropine 
completely inhibited the 3 fold increase in GMBF elicited by ic 
RX 77368 at 30 ng. Likewise, atropine completely blocked 
intracerebroventricular injection of TRH-induced 2 fold 
stimulation of GMBF in urethan-anesthetized rats (Thiefin 
1989). In dogs, atropine also blocked the increase in blood 
flow induced by vagal stimulation by 2-deoxy-D-glucose or 
insulin (Swan 1967) . In addition, acetylcholine infused intra­
arterially into the stomach increases GMBF and acetylcholine 
applied topically onto gastric submucosal arterioles induces
vasodilatation through atropine-sensitive mechanisms (Morishita 
1986; Kitagawa 1987a). By contrast, upon electrical vagal 
activation, gastric blood flow response involves an additional 
atropine-resistant component (Kitagawa 1987a; Thiefin 1990). 
Capsaicin sensitive vagal afferents (Thiefin 1990) and/or 
postganglionic release of non-adrenergic non-cholinergic 
vasodilators such as vasoactive intestinal peptide have been 
postulated to contribute to the atropine-resistant component of 
gastric hyperemia to electrical vagal activation (Ito 1988). 
Since medullary TRH plays a physiological role in the vagal 
efferent regulation of gastric function (Tache 1994a), it is 
tempting to speculate based on the present and previous data 
that under activation of medullary preganglionic vagal neurons, 
the underlying mechanisms increasing GMBF are mainly atropine- 
sensitive .
We examined whether the rise in GMBF resulted from a 
direct effect of acetylcholine or was secondary to a muscarinic 
mediated release of vasodilatory substances. RX 77368 injected 
ic stimulated the gastric generation of PGE2 and histamine 
release and activated the efferent function of capsaicin 
sensitive afferents through atropine-sensitive pathways 
(Yanagisawa 1990a; Yanagisawa 1990b; Yoneda 1993b). These 
transmitters contribute to the modulation of gastric acid 
secretion and resistance of the mucosa to injury elicited by ic 
RX 77368 (Yanagisawa 1990a; Yanagisawa 1990b; Yoneda 1993b; 
Tache 1993b). PGE2 and histamine, acting preferentially through 
H, receptors as well as CGRP contained in capsaicin sensitive 
afferents increase GMBF in rats (Guth 1987; Guth, 1991; Holm 
1992; Holzer, 1992a; Whittle, 1993). We previously showed that 
indomethacin, injected at a dose preventing the stimulation of 
gastric PGE2 formation elicited by ic injection of TRH-analog 
(Yanagisawa 1990b), did not influence the increase in GMBF 
induced by RX 77368 either at 1.5 or 30 ng (Király 1997b;
Tanaka 1997) . Likewise, electrical vagal stimulation- or intra­
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arterial injection of acetylcholine-induced gastric hyperemia 
is not altered by indomethacin in rats (Kitagawa 1987a; Király 
1997b). The present study shows that pyrilamine, infused at a 
dose which blocked H,-mediated vascular changes (Holm 1994), 
did not inhibit the GMBF response to ic injection of RX 77368. 
The H2 agonist, impromidine, does alter GMBF in rats at doses 
that stimulates acid secretion and intra-arterial infusion of 
histamine does not influence gastric vascular resistance (Holm
1994). Therefore, these data indicate that gastric histamine 
released by ic RX 77368 at 30 ng (Yanagisawa 1990a) is unlikely 
to play a role in gastric vascular changes induced by RX 77368. 
In addition, capsaicin, which is known to deplete CGRP from 
gastric afferent fibers (Holzer, 1992a), did not prevent the 
gastric hyperemic response to ic injection of TRH analog at a 
30 ng dose (Király 1997b), present observation. By contrast, 
capsaicin and intravenous injection of the CGRP antagonist 
prevented the increase in GMBF elicited by ic injection of RX 
77368 at a lower dose (1.5 ng) (Király 1997b). Therefore, these 
findings indicate that additional mechanisms come into play at 
a higher intensity of central vagal activation which increases 
GMBF.
The present findings support a primary role of peripheral 
L-arginine-NO synthase pathways in the muscarinic dependent 
stimulation of GMBF and decreases vascular resistance evoked by 
ic RX 77368 at 30 ng.
First, the organization of the gastric circulation 
requires submucosal arterioles to be dilated to increase GMBF 
(Guth 1987) and NO exerts an important vasodilatory influence 
in the gastric circulation (Pique 1989; Chen 1993) .
Second, RX 77368 injected ic at 30 ng stimulates gastric 
NO generation through vagal atropine-sensitive pathways 
(Saperas 1995).
Lastly, the NO synthase inhibitor, L-NAME injected iv 
completely abolished gastric hyperemia in response to ic
injection of RX 77368 at 30 ng dose in intact (Tanaka 1993) and 
capsaicin-pretreated rats (present study). L-NAME was reported 
to compete non-selectively at the agonist binding site of 
several forms of muscarinic receptors in in vitro assays 
(Buxton 1993). However, L-NAME action results from peripheral 
inhibition of NO synthase activity rather than a possible anti- 
muscarinic action. L-NAME inhibitory action in capsaicin- 
pretreated rats was reversed in a specific manner by an excess 
of L-arginine, a substrate for NO synthase while the D-arginine 
enantiomer was inactive. Moreover, L-NMMA, an inhibitor of 
endothelial NO synthase, which is devoid of muscarinic 
antagonist properties (Rees 1990; Buxton 1993) , also blocked 
the increase in GMBF and decrease in GMVR induced by RX 77368 
in intact rats. Lastly, L-NAME injected into the cisterna magna 
did not alter the gastric vascular responses to ic TRH analog. 
The biological activity of L-NAME injected ic was supported by 
the increase in basal MAP as previously observed using ic 
injection of other NO synthase inhibitors (Togashi 1992). 
Therefore, although systemic injection of L-NAME has been 
reported to decrease NO synthase in the rat forebrain (iadecola 
1994), a peripheral action is responsible for L-NAME-induced 
blockade of the gastric vascular responses to ic RX 77368.
The source of enhanced NO production most likely 
originates from endothelium where NO is abundantly synthesized 
(Palmer 1988). In addition, acetylcholine increases GMBF 
through endothelium-dependent mechanisms (Kitagawa 1987a) and 
direct superfusion of low doses of acetylcholine onto 
submucosal arterioles induced vasodilation which is prevented 
by L-arginine-NO pathways blockade (Chen 1993). Nitric oxide 
synthase is also found in postganglionic neurons of the 
parasympathetic system that innervate the stomach (Forster 
1993a). The neuronal NO serves as a peripheral non-cholinergic 
and non-adrenergic transmitter of gastric relaxation induced by 
high frequency electrical vagal stimulation (Lefebvre 1992). 
However, since atropine completely abolished the NO-dependent
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increase in GMBF induced by ic RX 77368, it is unlikely that 
neuronal NO contributes to the gastric vascular response.
Previous reports consistently showed that the hypertensive 
response to intracerebroventricular TRH is mediated by the 
sympathetic nervous system and catecholamine release while 
parasympathetic cholinergic mechanisms do not play a role 
(Mattila 1986; Siren 1988; Thiefin 1989) . Likewise, atropine 
did not alter the rise in MAP induced by ic injection of TRH 
analog at 30 ng. We also found that the increase in MAP induced 
by ic RX 77368 was not influenced by an excess of L-arginine. 
These results indicate that the hypertensive response to ic TRH 
analog is not related to autonomic mediated alterations of 
tonic NO generation in peripheral vascular beds (Lacolley 
1991). By contrast, the enhanced blood pressure response to ic 
RX 77368 by systemic injection of NO inhibitors was reversed in 
an enantiomeric manner by an excess of L- but not D-arginine. 
These results most likely reflect the additional increase in 
peripheral vascular resistance in various beds due to the 
removal of the continuous vasodilatory action of NO when NO 
synthase inhibitors are injected into the circulation (Pique 
1989; Rees 1989). Atropine, L-NAME or L-NMMA blocked the 
decrease in gastric vascular resistance induced by ic RX 77368 
while the increase in MAP was unchanged by atropine and further 
enhanced by NO inhibitors. These results further indicate that 
the increase in GMBF induced by central RX 77368 is not merely 
the result of changes in systemic arterial pressure but is 
likely to represent muscarinic-NO mediated vasodilatation 
occurring locally in the gastric submucosal arterioles.
In summary, the present observations demonstrate that ic 
injection of RX 77368 at 30 ng increases GMBF through atropine- 
sensitive mechanisms. In addition, NO, most likely originating 
from vascular endothelial cells, plays a crucial role in 
mediating the muscarinic-dependent stimulation of GMBF induced 
by central vagal activation in intact or capsaicinized rats. By 
contrast, other vasodilatory agents, namely histamine acting on
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H, receptor or indomethacin (Tanaka 1997) are not involved.
Since medullary TRH plays a physiological role in the vagal 
regulation of gastric function (Tache 1994a), these data may 
have a bearing on the underlying mechanisms through which GMBF 
is increased in response to central vagal activation. These 
studies also point out that central vagal stimulation by TRH 
may be a more relevant tool to assess the vagal regulation of 
gastric circulation compared with electrical vagal stimulation.
3.2.2.5 Perspectives
The present data demonstrate that central vagal efferent 
activation stimulates GMBF and decreases gastric vascular 
resistance through cholinergic and NO dependent pathways in 
rats. Further studies are needed to delineate the precise 
mechanisms by which central vagal efferent cholinergic 
activation is coupled or gated to the L-arginine-NO pathways in 
the gastric submucosal arterioles. Direct superfusion of low 
concentrations of acetylcholine on gastric submucosal 
arterioles dilate the arterioles through atropine sensitive and 
L-arginine-NO dependent mechanisms (Morishita 1986; Chen 1993). 
Therefore, acetylcholine released from post ganglionic neurons 
by central vagal activation may diffuse to the endothelium of 
gastric submucosal arterioles. As recent studies suggest 
differential coupling of M,, M3 and M5 muscarinic receptors to 
activate nitric oxide synthase (Wang 1996), muscarinic receptor 
subtypes which are involved in the generation of NO leading to 
the dilation of arterioles in the gastric mucosa and increased 
blood flow will need to be characterized.
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3.2.3 Mechanisms mediating gastric hyperemic and acid 
responses to central TRH analog at a cytoprotective dose
3.2.3.1 Background
TRH or the stable TRH analog, RX 77368, injected 
intracisternally or into the dorsal vagal complex results in a 
vagal cholinergic modulation of the resistance of the mucosa to 
gastric injury (Yoneda 1992; Yoneda 1993b; Tache 1994b; Kaneko 
1995a; Kato 1996) . In particular, recent studies indicate that RX 
77368 or TRH protects the gastric mucosa against ethanol lesions 
when injected intracisternally or into the dorsal motor nucleus 
of the vagus at low, but not high doses (Yoneda 1992; Kaneko 
1995a; Kaneko 1995b; Tanaka 1997).
Gastric mucosal microcirculation is an important factor in 
the resistance of the gastric mucosa against injury, particularly 
as it relates to ethanol-induced gastric lesions (Guth 1987; 
Whittle, 1993). The maximal effective intracisternal dose of RX 
77368 (1.5 ng) at which gastric protection against ethanol injury 
occurs is subthreshold to increase gastric acid secretion and 
intraluminal pressure although it stimulates vagal efferent 
activity (Yoneda 1992; Raybould 1990; O-Lee 1997; Yoneda 1993b). 
Vagal activation is known to increase GMBF (Guth 1987), however, 
whether GMBF is enhanced by RX 77368 at a cytoprotective dose is 
not known. The underlying mechanisms preventing acid secretion in 
the presence of vagal stimulation also compel further 
investigations.
We previously showed that the mechanisms involved in the 
gastric protection against ethanol lesions induced by RX 77368 at
1.5 ng is atropine sensitive and prostaglandin (PG), calcitonin 
gene-related peptide (CGRP) and nitric oxide dependent (Yoneda 
1993b; Yoneda 1992; Kato 1994; Király 1993). There is evidence 
that CGRP, the predominant neuropeptide localized in primary 
capsaicin sensitive afferent neurons in the rat stomach (Sternini 
1987) and PGE2 have vasodilatory properties in the gastric mucosal
microcirculation (Guth 1987; Whittle, 1993) and inhibit gastric 
acid secretion (Yoneda 1993b). Therefore, the aims of the present 
study were: (1) to examine the influence of intracisternal
injection of a low dose of TRH analog (1.5 ng) on GMBF, gastric 
mucosal vascular resistance (GMVR) and gastric acid secretion 
monitored simultaneously in urethane-anesthetized rats. (2) to 
assess the role of prostaglandins and CGRP contained in capsaicin 
sensitive afferent fibers (Sternini 1987) in mediating or 
modulating GMBF and gastric secretory responses to intracisternal 
injection of RX 77368 at 1.5 ng.
3.2.3.2 Materials and methods 
Drugs and Treatments
The following substances were used: the stable TRH analog, 
RX 77368, p-Glu-His-(3,3'-dimethyl)-Pro-NH2 (Ferring 
Pharmaceuticals Ltd., Feltham, Middx, U.K.), indomethacin, (Sigma 
Chemical Co., St. Louis, MO), capsaicin (Sigma), and hCGRP8.37 
(kindly donated by Dr. S. St. Pierre, Department of Biochemistry, 
University of Quebec, Montreal, PQ, Canada). RX 77368 was 
aliquoted in 0.1% bovine serum albumin (BSA) and 0.9% saline at 
a concentration of 3 /xg/10 pil, and kept frozen at -70 °C. The 
stock solution of RX 77368 was dissolved in 0.9% saline (pH 7.0) 
before intracisternal injection delivered in 10 //I followed by 10 
/xl of saline to flush the catheter. Indomethacin was dissolved in 
1% sodium-bicarbonate and hCGRP8.37 in 0.1% BSA containing 0.9% 
saline. Capsaicin was dissolved in vehicle (absolute ethanol, 
Tween 80 and 0.9% saline, 1010:80:v/v/v) .
Animal Preparations and Surgical Procedures
All the surgical procedures performed for simultaneous 
measurements of GMBF, MAP, and gastric acid secretion and drug 
administration were essentially the same as previously described 
in chapter 3.2.
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Simultaneous Measurements of GMBF, MAP, and Acid Secretion
After an equilibration period of 1 h, GMBF was measured by 
the hydrogen gas-clearance technique as previously described in 
chapter 3.2. In the same preparation, the gastric effluent was 
continuously collected and separated into 15 min fractions which 
were titrated with 0.01 N NaOH using an automatic titrator 
(Radiometer Copenhagen). Gastric acid output was expressed in 
Hmol/30 min.
Experimental Protocols
In all the experiments, repeated monitoring of GMBF was 
performed twice under basal conditions, and twice again for the 
30 min periods before and after intracisternal injection of RX 
77368 (1.5 ng). Gastric acid output reflects the 30 min periods 
before pretreatment (basal) and before and after intracisternal 
injection of RX 77368. MAP values were selected at 15 min before 
and after intracisternal injection RX 77368 as used for the 
calculation of GMVR.
Study 1. Effect of indomethacin.
After a 60 min basal period, indomethacin (5 mg/kg) or 
vehicle (1% NaHC03) was injected intraperitoneally in 0.3 ml and 
60é min later, RX 77368 (1.5 ng) was injected intracisternally.
The dose of indomethacin was selected based on the inhibition of 
gastric PGE2 release induced by intracisternal injection of RX 
77368 at 1.5 ng in urethan-anesthetized rats (Yoneda 1992; Yoneda 
1993b). Parameters were monitored during the basal period, and 30 
min periods before and after administration of RX 77368.
Study 2. Effect of capsaicin.
Rats were injected subcutaneously 3 times at 12-h intervals 
with either capsaicin (25, 50 and 50 mg/kg, 0.5 ml) or vehicle 
(absolute ethanol, Tween 80 and isotonic saline, 10:10:80:v/v/v, 
0.5 ml). The first capsaicin injection was performed under short
enflurane anesthesia. After 10-14 days, all the capsaicin- 
pretreated rats showed the disappearance of the corneal chemo- 
sensory reflex (eye wiping for 1-3 min) to a drop of 0.1% NH40H 
instillated into each eye when tested just before the experiment. 
After a 60 min basal period, RX 77368 (1.5 ng) was injected
intracisternally in vehicle- and capsaicin-pretreated rats. 
Parameters were monitored for 30 min periods before and after RX 
77368 administration.
Study 3. Effect of CGRP antagonist.
After a 60 min basal period, vehicle (0.1% BSA/saline: 0.3 
ml followed by 1.5 ml/h) or hCGRP8_37 (15 ng/kg bolus followed by 
3 jig/kg/h) was infused intravenously throughout the experimental 
period. The intracisternal injection of RX 77368 (1.5 ng) was
performed 60 min after the start of the iv infusion of vehicle or 
CGRP antagonist. The regimen of hCGRPg.37 administration was based 
on our previous study showing the complete inhibition of intra­
arterial a-CGRP-induced gastric mucosal hyperemia in urethan- 
anesthetized rats (Király 1994). Parameters were measured during 
the basal period and the 30 min periods before and after RX 77368 
administration.
Statistics
Results are expressed as means ± SEM. Comparisons between 
before and after intracisternal injection of RX 77368 were 
analyzed by Student's paired t-test. Comparisons between two 
groups were performed by Student's t-test. Multiple group 
comparisons were performed by ANOVA followed by Duncan's 
contrast. P<0.05 was considered statistically significant.
Király, 76
Király, 77
3.2.3.3 Results
Study 1. Effect of Indomethacin on the GMBF, GMVR, MAP and Acid 
Responses to RX 77368
In vehicle-pretreated groups, intracisternal injection of 
the TRH analog, RX 77368 at 1.5 ng resulted in a significant 
increase in GMBF values (ml/min/100 g) from 46.8 ± 5.3 to 100.6 
+ 20.9 during the periods 15 min before and 15-30 min after 
intracisternal RX 77358 injection respectively (Fig. 11). During 
the 45-60 min post injection, GMBF was returning to basal levels 
(67.7 ± 8.5 ml/min/100 g, n=6). MAP values (mm Hg) were 70.3 
± 2.1 at 15 min before intracisternal injection and rose to 84.3 
± 5.9 at 15 min after RX 77368 injection (Fig. 12). The onset of 
hypertensive response was rapid (within 1-2 min) and plateaued 
thereafter to return to basal levels 30-45 min after TRH analog 
injection (data not shown). GMVR (mmHg/ml/min/100 g) decreased 
from 1.50 ± 0.33 to 0.84 ± 0.08 during the periods 15 before and 
15-30 min after intracisternal injection of RX 77368 respectively 
(Fig. 12). Gastric acid secretion (/mol/30 min) did not change 
significantly before (1.8 ± 0.4) and after (4.7 + 1.7)
intracisternal RX 77368 injection (Fig. 11) . As previously 
reported (Király 1994) , intracisternal injection of saline in 
vehicle-pretreated rats did not change GMBF (ml/min/100 g: 51.7 
± 4.7 and 50.7 ± 5.5 during the periods 15 min before and 15-30 
min after saline respectively), GMVR (mmHg/ml/min/100 g: 1.83 ± 
0.13 and 1.85 ± 0.14 during the periods 15 min before and 15-30 
min after saline respectively) or MAP (mmHg: 94 ± 2 and 93 ± 3 at 
15 min before and after saline).
Compared with vehicle pretreatment, indomethacin (5 mg/kg, 
ip) did not influence basal GMBF, MAP and GMVR and tends to 
reduce basal gastric acid secretion in urethan-anesthetized rats 
(Figs. 11, 12). Indomethacin did not modify intracisternal RX 
77368 (1.5 ng)-induced gastric hyperemia (Fig. 11), rise in MAP 
and decrease in GMVR during the 15-30 min period post injection
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(Fig. 12) . However, intracisternal injection of RX 77368 (1.5 ng) 
induces a robust increase in gastric acid secretion in 
indomethacin-pretreated rats (19.7 + 2.9 /xmol/30 rain) while there 
was no significant increase (4.7 ± 1.7 ^mol/30 min) after RX 
77368 in vehicle-pretreated group (Fig. 12).
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Basal Vehicle INDO Basal Vehicle INDO
Fig. 11. rffect of indomethacin (1N0) on gastric mucosal blood flow (GMBF) and acid responses to 1.5 ng 
dose of RX 77368 injected intracisternaIly  ( ic ) .  INO (5 mg/kg. ip) or vehicle (0.3 ml. sc) was injected 
60 min before RX 77368 (1.5 ng. ic ). Fach coluir* represents the mean ± STM of 4-10 rats/grot*). *  P< 0.05 
(paired t-Lest) compared with respective values before RX 77368 injection: # P< 0.05 (unpaired t-te s t)  
compared with vehicle plus RX 77368-treated group. Gffir values are during the 15 min period before IND 
or vehicle (basal). 15 min period before intracistem al injection (before RX 77368) and 15-30 min after 
intracistem al injection (a fter RX 77368): acid secretion values are 30 min period before IND or vehicle
(basal) and before and after RX 77368.
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Fig. 17. Fffect of indnmethacin (IND) on wean arteria l pressure (NAP) and gastric mucosal vascular 
resistance (GMVR) responses to 1.5 ng of RX 77368 injected intracisternaIly  ( ic ) .  Similar treatments and 
animals as described in rig . 11. Each colimn represents the mean t SfN. *  P< 0.05 (paired t -te s t)  
compared with respective values 30 min before RX 77368 injection. NAP values are at 15 min before IND or 
vehicle (basal) and at 15 min before or after RX 77368: GHVR values are during the 15 min period before 
IND or vehicle (basal). 15 min period before intracistem al injection before and 15-30 min after
intracistem al injection of RX 77368.
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Study 2. Effect of capsaicin on the GMBF, GMVR, MAP and acid 
responses to RX 77368
Systemic capsaicin pretreatment did not alter the basal 
GMBF, MAP, GMVR and gastric acid secretion compared with vehicle- 
pretreated rats (Figs. 13, 14). The gastric hyperemia observed 
during the 15-30 min period after intracisternal injection of RX 
77368 (1.5 ng) was abolished by capsaicin-pretreatment (Fig. 13) 
while the rise in MAP was not modified (Fig. 14). Intracisternal 
RX 77368 which decreases GMVR in vehicle-pretreated rats, induced 
a significant elevation in GMVR in capsaicin-pretreated rats 
(Fig. 14) . During the 30 min period after intracisternal RX 77368 
(1.5 ng), there was also a significant increase in gastric acid 
output (8.7 ± 2.7 /xmol/30 min) in capsaicin-pretreated rats
compared with preinjection levels (1.6 ± 0.7 /xmol/30 min) (Fig. 
13) . In the vehicle-pretreated group, the 30 min gastric acid 
outputs before and after intracisternal injection of RX 77368 
were not significantly different (from 2.9 ± 0.8 to 6.2 ± 1.7 
/imol/30 min) (Fig. 13) .
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Fig. 13. Effect of sensory nerve ablation by systemic capsaicin pretreatment on gastric mucosal blood 
flow (GMBF). and acid responses to 1.5 ng of RX 77368 injected intracistem ally ( ic ) .  Capsaicin or 
vehicle was given s.c. at doses of 25. 50. 50 mg/kg on three consecutive days 10-14 days before RX 77368 
adninistration. Each colimn represents mean ± SEH of 4-6 rats/group. *  P< 0.05 (paired t-te s t)  compared 
with respective basal values; # P< 0.05 (unpaired t-te s t)  compared with vehicle plus RX 77368-treated 
group. GMBF values are during the 15 min period before and 15-30 min afte r intracistem al injection of 
RX 77368; acid secretion values are 30 min period before and afte r RX 77368.
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Fig. 11. Fffect of sensory nerve ablation by systemic capsaicin pretreatment on mean arteria l pressure 
(MAP) and gastric mucosal vascular resistance (GMVR) responses to 1.5 ng of RX 77368 injected 
in tracistem ally ( ic ) .  Similar treatment and animals as described in Fig. 14. Each coluwi represents mean 
± SEM of 4-6 rats/group. *  P< 0.05 (paired t-te s t)  compared with respective basal values; # P< 0.05 
(unpaired t-te s t)  conpared with vehicle plus RX 77368-treated group. MAP values are at 15 min before or 
after RX 77368; GMVR values are during the 15 min period before intracistem al injection (before RX 
77368) and 15-30 min after intracistem al injection (a fte r RX 77368).
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Study 3. Effect of CGRP receptor antagonist, hCGRP8.37 on the GMBF, 
GMVR, MAP and acid responses to RX 77368
The CGRP receptor antagonist, hCGRPg.37 (15 M9/kg iv bolus 
then infused intravenously (3 /zg/kg/h) for 60 min before and 
after intracisternal injection of TRH analog), did not influence 
basal values of GMBF, MAP, GMVR and gastric acid secretion 
compared with vehicle-pretreated group (Figs. 15, 16). However, 
hCGRPg.37 infused intravenously prevented RX 77368-induced 
stimulation of GMBF (Fig. 15) and the decrease in GMVR (Fig. 16) 
while the rise in MAP was maintained (Fig. 16). In the presence 
of CGRP receptor antagonist, intracisternal TRH analog tends to 
increase gastric acid secretion (27.3 ± 14.1 jzmol/30 min) 
compared with pre-injection values (6.6 ± 3.5 /zmol/30 min) and 
GMVR (mmHg/ml/min/lOOg: from 1.60 ± 0.17 to 2.01 ± 0.25) although 
the differences did not reach statistical significance (Figs. 15, 
16) .
Király, 84
Király, 85
3 3  before R X  7 7 368  
^  after R X  7 7 3 6 8  (1 .5  ng, ic)
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Fig. 15. Effect of hCGRPM7 on gastric mucosal blood flow (O W ) and acid responses to 1.5 ng of RX 77368 
injected intracistem al ly ( ic ) .  CGRP„7 (15 pg/kg + 3 pg/kg/h iv ) or vehicle (0.3 ml ♦ 1.5 ml/h. iv ) was 
started to in ject 60 min before RX 77368 adninistration. fach colum represents the mean ± SFM of 4-6 
rats/groip. *  P<0.05 (paired t-te s t)  compared with respective basal values; # P< 0.05 (unpaired t-te s t)  
conpared with vehicle plus RX 77368-treated groip. GWT values are during the 15 min period before 
hCGRIYj, or vehicle (basal). 15 min period before intracistem al injection (before RX 77368) and 15-30 
min afte r intracistem al injection (a fte r RX 77368); acid secretion values are 30 min period before 
hCGRPi  j7 or vehicle (basal) and before and after RX 77368.
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before RX 77368
after RX 77368 (1.5 ng, ic)
Basal Vehicle
Fig. 16. Effect of hCGRP937 on mean arteria l pressure (MAP) and gastric mucosal vascular resistance 
(GMVR) to 1.5 ng of RX 77368 injected intracisternally ( ic ) .  Similar treatments and animals as described 
in Fig. 15. Each colum represents the mean ± SEN of 4-6 rats/groip. *  P<0.05 (paired t-te s t)  compared 
with respective basal values: # P< 0.05 (impaired t-te s t)  compared with vehicle plus RX 77368-treated 
group. HAP values are at 15 min before hCGRPM7 or vehicle (basal) and at 15 min before or after RX 
77368: GMVR values are during the 15 min period before hCGRP^ 37 or vehicle (basal). 15 min period before 
intracisternal injection (before RX 77368) and 15-30 min afte r intracistem al injection (a fte r RX 77368).
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3.2.3.4 Discussion
The TRH analog, RX 77368, injected intracisternally at 1.5 
ng stimulated GMBF in urethan-anesthetized rats as measured 
within the 15-30 min period post injection by the hydrogen gas 
clearance technique. Peptide action at 1.5 ng was shorter lasting 
(less than 60 min) compared with the 30 ng dose tested under the 
same conditions (Tanaka 1993; Király 1994). The GMBF response 
represents a specific effect of the peptide as intracisternal 
injection of vehicle did not modify GMBF as reported previously 
(Király 1994). Convergent evidence in urethan-anesthetized rats 
indicates that the gastric hyperemia induced by the central 
injection of TRH or RX 77368 is mediated by vagal cholinergic 
dependent mechanisms (Thiefin 1989; Király 1994; Király 1998).
First, RX 77368 injected intracisternally at 1.5 ng 
stimulates gastric vagal efferent discharge within 5 min for over 
30 min post injection (Thiefin 1989; Tanaka 1993; Király 1994; 
Király 1998).
Second, the gastric hyperemia can be evoked by the direct 
microinjection of TRH into the dorsal motor nucleus of the vagus 
(0-Lee 1997) and abolished by vagotomy and peripheral, but not 
central, injection of atropine (Fantozzi 1978; Thiefin 1989). In 
addition, intravenous administration of the cholinergic agonist, 
bethanechol, mimics the increase in GMBF elicited by central 
vagal stimulation (Király 1994) . This contrasts with the gastric 
hyperemic response to electrical stimulation of the vagus which, 
in addition to cholinergic dependent mechanisms, involves an 
atropine-resistant component (Guth 1987).
The peripheral mechanisms by which intracisternal RX 77368 
at a low dose increases GMBF are not secondary to changes in acid 
secretion and prostaglandin release. In previous studies, TRH or 
RX 77368 was injected intracisternaly at doses which stimulated 
both gastric acid secretion and GMBF (Thiefin 1989; Tanaka 1993; 
Király 1994). There are examples of changes in regional GMBF in 
response to stimulation of gastric acid secretion (Guth 1987).
However, the stimulation in GMBF induced by RX 77368 at 1.5 ng 
occurs in the absence of a significant stimulation of gastric 
acid secretion as monitored simultaneously in the same animal 
preparation. RX 77368 injected intracisternally or into the 
dorsal motor nucleus of the vagus at low doses stimulates the 
gastric release of PGE2 which is blocked by vagotomy (Yoneda 
1993b; Kato 1995b). PGE2 is known to have a vasodilatory effect 
on the gastric mucosal microvessels (Guth 1987; Whittle, 1993). 
However, indomethacin injected at a dose which suppresses the 
stimulation of gastric PGE2 release in response to intracisternal 
RX 77368 at 1.5 ng (Yoneda 1993b), did not modify its gastric 
hyperemic response. Likewise, indomethacin did not influence the 
increase in GMBF (measured by the oxygen saturation of 
hemoglobin) evoked by electrical stimulation of the cervical 
vagus or intra-arterial injection of acetylcholine in rats 
(Kitagawa 1987b).
Convergent functional and anatomical evidence indicates that 
the CGRP contained in capsaicin sensitive afferent fibers plays 
an important role in the gastric hyperemia to RX 77368 injected 
intracisternally at 1.5 ng.
First, CGRP exerts a potent local vasodilatory effect in the 
gastric submucosal arterioles in rats (Chen 1992).
Second, gastric submucosal arterioles are densely innervated 
by capsaicin sensitive sensory nerves containing CGRP (Sternini 
1987) .
Lastly, both, capsaicin pretreatment or intravenous 
injection of hCGRPg_37 completely prevented the 100% increase of 
GMBF and decrease in gastric vascular resistance induced by 
intracisternal RX 77368 at 1.5 ng. Systemic capsaicin 
pretreatment was shown to ablate CGRP immunoreactivity contained 
in splanchnic neurons innervating gastric blood vessels (Sternini 
1987) . hCGRP8.37 is a specific CGRP receptor antagonist (Dennis 
1990) previously reported to abolish intravenous CGRP-induced 
gastric hyperemia in rats (Király 1994). The lack of effect of
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these treatments on basal GMBF, as previously reported (Király 
1994), indicate that CGRP contained in capsaicin sensitive 
afferents does not contribute to the basal regulation of GMBF in 
urethan-anesthetized rats. Close intra-arterial infusion of the 
muscarinic agonist, bethanechol, increases GMBF and the gastric 
hyperemia was abolished by intravenous infusion of the CGRP 
antagonist in urethan-anesthetized rats (Király 1994). Likewise 
in the perfused mesenteric vascular beds isolated from rats, 
acetylcholine induced a prolonged vasodilation mediated by CGRP 
release from capsaicin sensitive afferents (Takenaga 1995). 
These data along with the demonstration that gastric circulation 
requires* submucosal arterioles to be dilated to increase GMBF 
(Guth 1987), suggest that a cholinergic-CGRP dependent 
vasodilation of gastric arterioles may play an important role in 
the gastric hyperemic response to central RX 77368 at 1.5 ng 
(Fig. 17.).
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Fig. 17. Schematic representation of the action of RX 77368 injected at a cytoprotective dose (1.5 ng ic) 
in the dorsal vagal complex (DVC) to induce vagal muscarinic dependent stimulation of gastric secretion 
of histamine, prostaglandin Fz (PGf}) calcitonin gene-related peptide (CGRP) n itr ic  oxide (NO) and gastric
mucosal blood flow (GMBf)
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We recently reported that intracisternal injection of RX 
77368 at a maximal gastric secretory dose (30 ng) stimulated GMBF 
also through vagal cholinergic and CGRP dependent mechanisms 
whereas substance P did not play a role (Király 1994). However, 
in capsaicinized rats, an alternate pathway involving nitric 
oxide was able to maintain the hyperemic response independently 
of CGRP (Király 1994) (Fig.18.).
I ig. 18. Schematic representation <>( ütő action of IIX //36fl injected at a maximal acid secretory dose (30 
ng ic ) in the dorsal vagal conplex (l)VC) to induce vagal muscarinic dependent stimulation oT gastric  
secretion of histamine, prostaglandin l 2 ( P C , I 2 ) calcitonin  gene-related peptide (CGRP) n it r ic  oxide (NO)
and gastric mucosal blood flow (GMHI)
By contrast, the present findings show that when RX 77638 is 
injected intracisternally at a submaximal acid secretory dose, 
the "efferent function" of capsaicin sensitive afferents 
releasing CGRP (Holzer, 1988) represents the main underlying 
mechanism whereby the gastric hyperemic response occurs. 
Therefore, depending upon the level of central stimulation of the 
vagus alternate route/or cascades are recruited and come into 
play (Figs. 17, 18.).
RX 77368 injected intracisternally at 1.5 ng elevated MAP as 
previously reported for central injection of TRH or RX 77368 at 
higher doses (Mattila 1986; Thiefin 1989; Király 1994). The 
hypertensive response is not altered by inhibition of 
prostaglandins or CGRP contained in capsaicin sensory afferents. 
Previous pharmacologic and nerve ablation studies indicated that 
the rise in blood pressure induced by central injection of TRH 
did not involve vagal cholinergic mechanisms, but is related to 
changes in sympathetic outflow in rats (Mattila 1986; Siren 1988; 
Thiefin 1989). In particular, intracerebroventricular injection 
of TRH increases the splanchnic nerve activity in the adrenal and 
renal branches as well as elevates circulating levels of 
catecholamine (Brown, 1981; Somiya 1984; Mattila 1986). By 
contrast, there is a decrease in splanchnic nerve activity in the 
gastric branch (Somiya 1984). In capsaicin- or CGRP antagonist- 
pretreated rats, intracisternal RX 77368 at 1.5 ng increased, 
instead of decreasing GMVR, suggesting vasoconstriction of 
gastric vessels. Whether alterations in sympathetic activity and 
catecholamine release modulate the vagal dependent gastric 
hyperemic response to intracisternal injection of RX 77368, 
particularly when the local vasodilatory effect of CGRP is 
removed, needs to be further investigated.
An adequate level of blood flow is essential for gastric 
mucosal tissue to withstand the challenge of both endogenous and 
exogenous aggressors (Whittle, 1993). Intracisternal injection of 
RX 77358 at 1.5 ng is maximally effective to protect the gastric 
mucosa against ethanol injury (Kato 1995b). The increase in GMBF
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induced by RX 77368 at 1.5 ng may contribute, at least in part, 
to the gastroprotective effect since capsaicin and CGRP 
antagonist abolished both the gastric protection against ethanol 
(Kato 1994; Kato 1995b) and the gastric hyperemia observed at 
such an intracisternal dose of RX 77368.
While GMBF is increased by intracisternal RX 77368 at 1.5
ng, gastric acid secretion was not significantly modified as
previously reported (Raybould 1990; Yoneda 1993b). The lack of an
acid secretory response in the presence of an activation of
gastric vagal efferent discharges (0-Lee 1997) may result from
the inhibitory effect of gastric prostaglandins and CGRP. We
previously showed that intravenous injection of PGE2 or a-CGRP
inhibits gastric acid secretion stimulated by vagal cholinergic*
pathways in urethan anesthetized rats (Saperas 1991; Tache, 
1992). Indomethacin induces a robust increase in gastric acid 
secretion in response to intracisternal RX 77368 at 1.5 ng while 
there was no significant secretory response to the same dose of 
RX 77368 in the vehicle-pretreated rats. In addition, depletion 
of CGRP from gastric afferent fibers by capsaicin pretreatment 
(Sternini 1987; Raybould 1992) also significantly stimulated 
gastric acid secretion after RX 77368 while there was no 
significant increase in vehicle-pretreated rats. Moreover, 
blockade of CGRP receptors by peripheral infusion of hCGRPg.37 
tends to increase acid secretion in response to intracisternal RX 
77368, although the difference did not reach statistical 
significance. The dose of CGRP antagonist used (18 ng/kg/h) 
abolished close intra-arterial infusion of a-CGRP (14 jxg/kg/h) 
and endogenous CGRP-induced increase in GMBF (Király 1994) 
(present study). However such a dose may be submaximal to prevent 
endogenous CGRP action on acid secretion. In a previous dose 
response study, an intravenous dose of 400 ng/kg of hCGRP8.37 was 
required to abolish intravenous injection of a-CGRP (14 ng/kg)- 
or endogenous CGRP-induced inhibition of gastric acid secretion 
in urethan-anesthetized rats (Kato 1995a).
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Growing evidence indicates that medullary TRH plays a 
physiological role in the vagal regulation of gastric function 
and resistance of the gastric mucosa against injury (Kato 1994; 
Tache 1994a; Kaneko 1995a) suggesting that medullary TRH may be 
involved in the central vagal regulation of GMBF. The present 
observations also lend further support to the concept that 
central vagal cholinergic activation recruits the "local effector 
function" of capsaicin sensitive afferent fibers containing CGRP 
in the rat stomach (Holzer, 1988).
In summary, TRH analog injected intracisternally at a low 
dose protecting the gastric mucosa against ethanol injury and 
stimulating gastric vagal efferent activity, induced a 100% 
increase in GMBF for the 30 min period post injection while not 
stimulating significantly acid secretion. The gastric hyperemic 
response is mediated by the vasodilatory action of CGRP released 
from capsaicin sensitive afferent nerves while changes in gastric 
prostaglandins and acid secretion do not play a role. The lack of 
acid response is due to the inhibitory influence of vagally 
released gastric prostaglandins and CGRP. These results indicate 
a cross talk between vagal efferent activation and capsaicin 
sensitive splanchnic afferents containing CGRP which has 
implication in the understanding of peripheral pathways mediating 
gastric secretory and hyperemic responses to a low level of 
central vagal activation.
3.2.4 VIP and central TRH-induced vasodilation: influence of 
a VIP antagonist: [4C1-D-Phe6,Leu17] VIP
3.2.4.1 Background
Vasoactive intestinal peptide (VIP) is well established to 
induce relaxation of vascular and non vascular smooth muscles 
(Fahrenkrug, 1993). In particular, Holzer and Guth (Holzer 1991a) 
showed that close intra-arterial infusion of VIP increases 
gastric mucosal blood flow (GMBF) at a dose decreasing blood 
pressure in urethane-anesthetized rats. VIP immunoreactive 
enteric neurons receive vagal input and project to the gastric 
muscuralis mucosae, circular smooth muscle and innervate small 
blood vessels in rats (Berthoud, 1996) . High frequency electrical 
vagal activation stimulates VIP release from the rat stomach 
through atropine resistant mechanisms (Ito 1988; Ishihara 1992b; 
Quian 1996) . Consistent reports indicate that the gastric 
vasodilatory response to electrical vagal stimulation involve an 
atropine-resistant component particularly at high frequencies of 
vagal activation (Morishita 1986; Kitagawa 1987b; Thiefin 1990). 
VIP has been reported to be a prime candidate in the vasodilatory 
response induced by electrical vagal activation of high threshold 
fibers in various vascular beds as shown by an 
immunoneutralization strategy with VIP antibody (Bloom 1980; 
Lundberg 1980) .
Medullary thyrotropin releasing hormone (TRH) is involved in 
the central vagal regulation of gastrointestinal function (Tache 
1994a) . TRH or the stable TRH analog, RX 77368, injected into the 
cerebrospinal fluid induces a vagal dependent stimulation of GMBF 
(Thiefin 1989; Tanaka 1993; Király 1994) and vagal independent 
increase in arterial pressure (Mattila 1986; Siren 1988; Thiefin 
1989; Király 1998). There is pharmacological evidence that VIP is 
part of the vagal dependent mechanism through which 
intracerebroventricular injection of TRH stimulates pancreatic 
exocrine and intestinal secretion (Lenz 1989; Messmer 1993; Lenz
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1995). The possible role of VIP in mediating or modulating the 
hemodynamic changes induced by intracisternal injection of TRH is 
unknown. Previous studies indicate that the VIP analog, [4C1-D- 
Phe6, Leu17] VIP, is a selective competitive VIP antagonist in 
several in vitro or in vivo systems (Pandol 1986; Grider 1990; 
Lenz 1995) . Therefore, in the present study, we test first 
whether [4C1-D-Phe6, Leu17] VIP antagonizes VIP-induced systemic and 
gastric vascular changes in urethane-anesthetized rats. Secondly, 
we investigated whether the VIP antagonist modulates the gastric 
hyperemic and hypertensive responses to intracisternal injection 
of the TRH analog, RX 77368. The TRH analog was used at a dose of 
30 ng which evokes a sustained increase in gastric vagal efferent 
activity, and GMBF in urethane-anesthetized rats (O-Lee 1997).
■k
3.2.4.2 Methods
Király, 96
Drugs
The following substances were used: the stable TRH analog, 
RX 77368, (p-Glu-His-(3,3'-dimethyl)-Pro-NH2) (Reckitt & Colman, 
Kingston-upon-Hill, England), rat VIP (Peninsula, Belmont, CA) 
and [4C1-D-Phe6, Leu17] VIP (Clayton Foundation Laboratories, Salk 
Institute, La Jolla, CA). The VIP antagonist was synthesized and 
purified by high performance liquid chromatography. RX 77368 was 
aliquoted in 0.1% bovine serum albumin (BSA) and 0.9% saline at 
a concentration of 3 ^g/10 jzl, and kept frozen at -70 °C. The 
stock solution was dissolved in 0.9% saline (pH=7.0) before 
administration. VIP was dissolved in 0.1% BSA containing 0.9% 
saline, and VIP-RA in 0.9% saline.
Animal preparation and surgical procedures
All the surgical procedures performed for simultaneous 
measurements of GMBF and mean arterial blood pressure (MAP) and 
for drug administration were essentially as previously described 
in Chapter 3.2 . l . 2 .
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Experimental Protocols
After one basal measurement of GMBF and MAP, vehicle or the 
VIP receptor antagonist, [4C1-D-Phe6, Leu17] VIP (2 /xmol/kg/h) was 
infused into the jugular vein throughout the duration of the 
experiment. Thirty min thereafter, vehicle or VIP (0.022 
jtmol/kg/h) was infused into the splenic artery at a rate of 25 
1xl/min for 30 min. In other studies, vehicle or [4C1-D- 
Phe6, Leu17] VIP (2 /xmol/kg/h) was infused into the jugular vein 
throughout the duration of the experiment and 30 min after the 
start of the infusion, RX 77368 (30 ng) was injected
intracisternally. GMBF was monitored before treatment (basal), 
during the 15-30 min period after the start of vehicle or [4C1-D- 
Phe6, Leu17] VIP infusion and during the 15-30 min period after VIP 
or RX 77368 administration in vehicle- and VIP antagonist-treated 
groups.
Statistics
Results are expressed as means ± SEM. Comparisons between 
two groups were calculated by Student's t-test. Comparisons 
before and after treatments were analyzed by Student's paired t- 
test. Multiple group comparisons were performed by ANOVA followed 
by Duncan's contrast. P<0.05 was considered statistically 
significant.
3.2.4.3 Results
Basal GMBF and MAP were 54.1 ± 7.3 ml/min/100 g and 7 1 + 2  
mmHg respectively in urethane-anesthetized rats (Fig. 19). Close 
intra-arterial infusion of VIP (0.022 ^mol/kg/h) significantly 
increased GMBF to 82.1 ± 2.6 ml/min/100 g and lowered blood 
pressure to 60 ± 1 mmHg, while vehicle had no effect (Fig. 19). 
Systemic iv infusion of the VIP receptor antagonist, [4C1-D- 
Phe6, Leu17]-VIP (2 /zmol/kg/h) completely abolished intra-arterial 
injection of VIP-induced stimulation of GMBF and hypotensive 
response (Fig. 19). The VIP receptor antagonist did not influence
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basal levels of these parameters (Fig. 19).
In vehicle-pretreated rats, intracisternal injection of the 
TRH analog, RX 77368 (30 ng) stimulated GMBF (ml/min/100 g) from 
basal levels of 53.5 ± 3.3 to 123.6 ± 16.1, and increased blood 
pressure (mmHg) from basal levels of 76 ± 4 to 112 ± 5, (Fig. 
20) . In the presence of VIP antagonist infusion (2 jumol/kg/h) , 
RX 77368 injected ic (30 ng) significantly stimulated GMBF to 
109.6 ± 23.7 ml/min/100 g and the magnitude of the response was 
not significantly different compared with the vehicle-pretreated 
group (Fig. 2 0A) . The VIP antagonist, which had no effect on 
basal MAP (75 + 5 mmHg compared with basal 76 ± 4 mmHg) ,
potentiated the hypertensive response to ic RX 77368 (137 ± 7
mmHg) (Fig. 20B).
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Fig. 19. Fffect of VIP receptor antagonist. MCl-D-Phe*.leu” ]VIP. on gastric mucosal blood (O W ) and 
mean arteria l pressure (MAP) changes induced by close arteria l infusion of VIP in urethan-anesthetized 
rats. After basal measurements, vehicle or the VIP receptor antagonist ms infused (2 pmol/kg/h.) 
intravenously and 30 min la te r, vehicle (25 pl/min. white colimns) or VIP (0.022 pmol/kg/h) ms infused 
into the splenic artery for 30 min. Fach colum represents mean i STM of 4-9 rats/group: *  P< 0.05 
compared with respective basal values: + P< 0.05 compared with vehicle + VIP treated group. HAP 
represents values taken at 15 min before treatment (basal). 15 min afte r infusion of vehicle or VIP-RA 
and 15 min after VIP infusion in presence of vehicle or VIP-RA treatment. GHBF values correspond to the
same period.
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Fig. 20. Effect of VIP receptor antagonist. MCl-D-Phe, .Leu,7]VIP. on increase of gastric mucosal blood 
flow (GMBD and mean arteria l pressure (MAP) imkiced by intracistem al injection of RX 77368 in urethan- 
anesthetized rats. After a basal measurement, vehicle (1.5 ml/h. iv ) or the VIP receptor antagonist (2 
/jmol/kg/h, iv ) was infused and 30 min later, vehicle or RX 77368 was injected intracistem ally . Each 
col urn represents mean ± SFM of 5-12 rats/gro^): *  P< 0.05 compared with values before RX 77368; *  P< 
0.05 compared with vehicle + RX 77368 treated group. HAP represents values taken 15 min afte r infusion of 
vehicle or VIP-RA and 15 min afte r ic injection o f RX 77368 in vehicle or VIP-RA treated groups. OBF
values correspond to the same time period.
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3.2.4.4 Discussion
In the present study, close intra-arterial infusion of VIP 
(0.022 /tmol/kg/h) increased blood flow in the gastric mucosa by 
52% at a dose that lowered MAP by ll mmHg in urethane- 
anesthetized rats as previously reported under similar conditions 
(Holzer 1991a) . The rise of GMBF while there was a reduced 
perfusion pressure reflects an effective dilatation of gastric 
mucosal blood vessels in response to VIP infusion as reported in 
other vascular beds in rats (Bloom 1980; Ito 1987; Fahrenkrug,
1993) . In dogs, intra-arterial administration of VIP also caused 
gastric vasodilatation (Ito 1988) . The vascular responses to 
close intra-arterial injection of VIP namely the increase in 
GMBF, and decrease in MAP were completely prevented by 
intravenous injection of 2 /imol/kg/h of [4C1-D-Phe6, Leu17] VIP. The 
1:100 agonist-antagonist ratio used in the present study to block 
VIP action is similar to that reported to be effective in other 
in vitro or in vivo assays (Pandol 1986; Lenz 1989) . These 
results represent the first demonstration that [4C1-D- 
Phe6, Leu17] VIP is an antagonist for VIP-induced systemic or gastric 
vascular changes in the rat. Only one previous report in dogs 
showed the antagonistic action of [4C1-D-Phe*, Leu17]VIP infused 
into the coronary artery on VIP-induced increase in mean coronary 
blood flow (Quebbmann 1991) . Other in vitro studies assessed the 
antagonist action of [4C1-D-Phe6, Leu17] VIP in relation VIP-induced 
stimulation of intestinal or pancreatic secretion or smooth 
muscle relaxation (Pandol 1986; Algazi 1989; Grider 1990). 
Recently two VIP receptor subtypes, VIP, and VIP2 have been cloned 
from rat tissue DNA libraries (Ishihara 1992a; Lutz 1993; Usdin
1994) . Pharmacological characterization revealed that [4C1-D- 
Phe6, Leu17] VIP antagonizes cAMP accumulation in cells transfected 
with the rat VIP, receptor while having no effect in cell 
transfected with the rat VIP2 receptors (Rang 1991; Ishihara 
1992a; Lutz 1993). Therefore, [4C1-D-Phe6, Leu17] VIP appears to be
more selective for the VIP, than the VIP2 receptor subtype. These 
findings added to the more common association of VIP, receptor 
with blood vessels (Usdin 1994), suggest that exogenous VIP- 
induced decrease in blood pressure and increase in GMBF are 
mediated by an interaction with the VIP, receptor subtype. The 
absence of changes in basal MAP, and GMBF by the peripheral 
infusion of the VIP antagonist indicates that VIP does not 
participate in the maintenance of systemic and gastric vasomotor 
tone under basal conditions in urethane-anesthetized rats. 
Likewise in dogs, intracarotid infusion of [4C1-D-Phe6, Leu17] VIP 
did not document a role for VIP in regulating basal coronary 
arterial tone (Quebbmann 1991).
Consistent reports indicate that vagal stimulation at high 
frequency (10 Hz) or electrical field stimulation increases VIP 
release from various vascular beds through atropine resistant 
mechanisms (Ito 1987; Ito 1988; Holst 1992; Ishihara 1992b; Quian
1996) . Intracisternal injection of RX 77368 in doses as low as
1.5 ng stimulates vagal efferent discharges in urethane- 
anesthetized rats (0-Lee 1997). There is also evidence that VIP 
mediates the atropine resistant component of 
intracerebroventricular injection of TRH-induced vagal dependent 
stimulation of exocrine pancreatic and duodenal bicarbonate 
secretion and intestinal transport suggesting an endogenous 
release of VIP by central TRH (Lenz 1989; Messmer 1993; Lenz
1995). In the present study, VIP receptor blockade by systemic 
infusion of [4C1-D-Phe6, Leu17] VIP enhanced the rise in MAP induced 
by ic RX 77368 by 25 mmHg while the VIP antagonist alone did not 
influence basal MAP. Previous studies indicate that RX 77368 
injected ic at 30 ng or central injection of TRH increased MAP 
through atropine resistant mechanisms secondary to stimulation of 
the sympathetic nervous system (Mattila 1986; Siren 1988; Thiefin 
1989; Király 1998). Taken together these results suggest that 
endogenous VIP modulates the hypertensive response to ic RX 77368 
by counteracting the increase in blood pressure owning to its
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hypotensive effect . Previous studies showed that blockade of 
other vasodilatory substances, such as nitric oxide synthase 
inhibitor, L-NAME or L-NMMA further enhanced the rise in blood 
pressure induced to ic RX 77368 at 30 ng while calcitonin gene- 
related peptide antagonist, hCGRP8.37 did alter the hypertensive 
response (Tanaka 1993; Király 1994; Király 1998). Therefore, the 
rise in systemic blood pressure induced by central injection of 
RX 77368 represents the net effect of substances released by 
autonomic activation having opposite modulatory influences on 
vascular tone.
RX 77368 injected ic at 30 ng stimulates GMBF by 2.3 fold 
above basal in urethane anesthetized rats as previously reported 
(Raybould 1990; Tanaka 1993; Király 1994; Király 1998). In the 
presence of intravenous infusion of [4C1-D-Phe6, Leu17] VIP, RX 77368 
injected ic increased GMBF by 2 fold above basal and there was no 
significant difference in the magnitude of the response compared 
with vehicle-treated group. It is unlikely that lack of 
significant influence of the VIP antagonist be related to the 
higher stimulation of GMBF induced by ic injection of RX 77368 
compared with iv infusion of VIP. The VIP antagonist was used at 
a dose that blocked infusion of VIP at 22 nmol/kg/h. These 
results indicate that VIP is not the primary mediator of the 
increase in GMBF induced by ic RX 77368 at 30 ng. The stimulation 
in GMBF induced by central injection of TRH or intracisternal 
injection of RX 77368 at 30 ng was previously reported to be 
completely abolished by vagotomy and atropine (Thiefin 1989; 
Király 1998) . By contrast, VIP is a prime candidate for the non- 
adrenergic non-cholinergic (NANC) gastric relaxation and 
stimulation of blood flow in various beds observed after high 
frequency electrical vagal stimulation (Bloom 1980; Guth 1987; 
Ito 1987; Ito 1988; Thiefin 1990; Ishihara 1992b). Therefore, the 
stimulation of GMBF induced by ic RX 77368 in the presence of the 
VIP receptor antagonist is consistent with the response being 
primarily mediated by atropine sensitive-nitric oxide pathways
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(Tanaka 1993; Király 1998). Since medullary TRH plays a 
physiological role in the vagal efferent regulation of gastric 
function (Tache 1994a), it is tempting to speculate based on the 
present and previous data that under activation of medullary 
preganglionic vagal neurons, the underlying mechanisms increasing 
GMBF does not involved NANC VIP mediated mechanisms.
In summary, the present study shows that systemic injection 
of [4C1 -D-Phe6, Leu17] VIP at 2 /zmol/kg/h is an effective antagonist 
of VIP-induced hypotension and increase in GMBF in rats. There is 
no evidence for VIP being involved in the maintenance of normal 
resting systemic blood pressure and gastric blood flow in 
urethane anesthetized rats. However, upon autonomic activation by 
ic injection of RX 77368, endogenous VIP attenuates significantly 
the systemic pres«or response to the central TRH analog. By 
contrast, VIP does not appear to play a primary role in the vagal 
dependent-atropine sensitive increase in GMBF induced by RX 77368 
at such a dose.
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3.3 Communication between vagal efferents and splanchnic sensory 
afferents: role of vagally activated gastric mucosal mast cells
3.3.1 Gastric hyperemia induced by intracistemal TRH analog 
at a cytoprotective dose is prevented by ketotifen
3.3.1.1 Background
We recently demonstrated that the gastric mucosal hyperemia 
and gastric protection induced by i.c. RX 773 68 at 1.5 ng are 
mediated by vagal muscarinic dependent pathways and calcitonin 
gene-related peptide (CGRP) contained in capsaicin-sensitive 
afferent fibers (Király 1997b). The mechanisms recruiting the 
"local effector fuhction" of capsaicin-sensitive afferent nerve 
endings (Holzer, 1988; Maggi 1988) in the stomach after central 
activation of gastric vagal efferent discharges by RX 77368 
injected i.c. at a low dose (0-Lee 1997) are still unknown.
Earlier studies indicate that electrical vagal stimulation 
activates mast cells in the gastrointestinal mucosa and submucosa 
(Cho 1977; Gottwald 1995; Santos 1996) . In addition, consistent 
association of mast cells and neurons containing either substance 
P or CGRP has been demonstrated in the rat mesentery (Stead 1987; 
Crivellato 1991). Therefore, mast cell-derived substances known 
to activate capsaicin-sensitive afferent fibers (Maggi, 1991; 
Akoev 1996) may play an intermediary role in mediating the 
capsaicin and CGRP dependent gastric hyperemic response to i.c. 
RX 77368 at 1.5 ng. In the present study, we assessed the 
influence of the mast cell stabilizer, ketotifen (Grant 1990) on 
the increase in gastric mucosal blood flow induced by RX 773368 
injected i.c. at a low dose in urethane-anesthetized rats.
3.3.1.2 Material and Methods
Drugs
RX 77368, [p-Glu-His-(3,3 -dimethyl)-Pro-NH2; Ferring
Pharmaceuticals Ltd., Feltham, Middlesex, UK] was stored in a 
stock solution (3 ^g/10 /xl, 0.1% bovine serum albumin/saline) at 
-70° C. The stock solution of RX 77368 was dissolved in 0.9% 
saline (pH=7.0) before injection. Ketotifen (Sigma Chemical Co, 
St Louis, MO) was dissolved in 0.9% saline.
Animals and Surgeries
All the surgical procedures performed for simultaneous 
measurements of gastric mucosal blood flow, mean arterial 
pressure, and gastric acid secretion, as well as drug 
administration were essentially as previously described (Chapter 
3.2.1.2) (Király 1994; Király 1997b).
Experimental procedures
The gastric mucosal blood flow was measured twice before 
(basal) and once after administration of ketotifen (2 mg/kg i.v. 
bolus followed by an infusion of 2 mg/kg/h throughout the 
experiment) or vehicle (0.3 ml followed by 1.5 ml/h infusion 
throughout the experiment). Thirty minutes after the start of the 
intravenous infusion of ketotifen or vehicle, RX 77368 (1.5 ng) 
was injected i.c. in 10 /xl in both vehicle- and ketotifen- 
pretreated groups and gastric mucosal blood flow was measured for 
the 60-min period post injection. Mean arterial pressure values 
were analyzed under basal conditions, at 15 min after i.v. 
infusion of vehicle or ketotifen and at 15 and 45 min after i.c. 
injection of RX 77368. The dose of TRH analogue was based on 
previous experiments showing an increase in gastric mucosal blood 
flow through vagal capsaicin- and CGRP-dependent pathways (Király 
1997b) . The dose of ketotifen was based on a previous in vivo 
study showing mast cell stabilizing properties (Grant 1990).
Statistics
Results are expressed as means ± S.E.M. Data were analyzed 
with ANOVA followed by Student-Newman-Keuls multiple comparisons
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test. MAP results before and after i.c. injection of RX 77368 
within the same group were also analyzed by a paired t-test. 
P<0.05 was considered statistically significant.
3.3.1.3 Results
Basal values of gastric mucosal blood flow were 52.4 ± 5.5 
ml/min/100 g, mean arterial blood pressure, 70 ± 4 mmHg, gastric 
mucosal vascular resistance, 1.5 ± 0.2 mmHg/ml/min/100 g and 
gastric acid secretion, 2.2 ± 0.2 ^mol/30 min in urethane
anesthetized rats (Fig. 21, Table 4) . Intravenous infusion of the 
vehicle for 15-30 min period did not modify these parameters 
(Fig. 21, Table 4). In vehicle-infused rats, RX 77368 injected
i.c. at 1.5 ng increased gastric mucosal blood flow to 141.8 ± 
18.1 ml/min/100 g (P<0.05) and decreased gastric mucosal vascular 
resistance by 59% (0.6 ± 0.1 mmHg/ml/min/100 g, P<0.05) as
monitored during the 15-30 min period after TRH analog injection; 
at the 45-60 min period, these changes are returning to basal 
levels (Fig. 21A,B). Systemic blood pressure was increased to 82 
± 6 mmHg (P<0.05, paired-t-test) at 15 min after i.c. injection 
of RX 77368 and values were returned to basal levels at 45 min 
(Fig. 21C) . There were no significant changes in gastric acid 
secretion induced by i.c. injection of RX 77368 at 1.5 ng during 
the 60 min period post injection (Table 4).
Ketotifen alone (2 mg/kg i.v. bolus, and 2 mg/kg/h, i.v. 
infusion) did not alter basal gastric mucosal blood flow, gastric 
vascular resistance, mean arterial pressure and gastric acid 
secretion as monitored during the first 15-30 min period (Fig. 
21, Table 4). Ketotifen completely prevented i.c. RX 77368 at 1.5 
ng-induced increase in gastric mucosal blood flow and values were 
maintained similar to basal level throughout the 60 min 
experimental period (Fig. 21A). The decrease in gastric mucosal 
vascular resistance induced by i.c. injection of RX 77368 at 1.5 
ng was abolished by ketotifen and values (mmHg/ml/min/100 g) were
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Vehicle (0 3 ml. i v ) Ketotifen (2 mg/kg. i v )
Vehicle (1.5 ml/h) f ~~1Ketotifen (2 mg/kg/h) I v M l)
-45 -30 -15 0 15 45 60
-45 -30 -15 0 15 45 60
TIME (min)
Fig. 21. Time course of the ketotifen (2 mg/kg + 2 mg/kg/h. iv . stripped colums) or vehicle (0.3 ml + 
1.5 ml/h. iv . white colums) effect on RX 77368 injected intrac istem ally  ( i  c l induced changes in 
gastric mucosal blood flow. GMBf (A), gastric mucosal vascular resistance. GMVR (B). and mean arteria l 
pressure. MAP (C) in urethane-anestheti/ed rats, fach colum represents the mean + ST.M. of 4-6 rats. *  
P< 0.05 compared with basal levels (-15 min); + P< 0.05 conpared with vehicle plus RX 77368-treated 
group. GMRI and fXVR values represent the 15-min period from the time indicated in min.
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Table 4. Gastric acid secretion in response to i.c. injection of RX 77368 (1.5 ng) in ketotifen- or
vehicle-treated urethane anesthetized rats
Treatment
a
N Gastric acid output ( \ imol/30 min)b 
Time (min)
Basal 0 30 60
Vehicle 6 2 . 3±0.5 4.3±1.7 5 . 1±1.5 3 . 0±0 . 7
Ketotifen 4 2 . 1±0.6 2.6±0.7 3 . 5±1.0 3 . 7±0 . 9
a After basal measurements, two groups of rats were injected i.v. 
with vehicle (0.3 ml) or ketotifen (2 mg/kg) followed by i.v. 
infusion of vehicle (1.5 ml/h) or ketotifen (2 mg/kg/h) for 30 
min before and 60 min after i.c. injection of RX 77368 (1.5 ng.).
Acid secretion was monitored throughout the study and represents 
30 min periods without treatment (basal) after vehicle or 
ketotifen treatment alone (0 time) and after i.c. injection of RX 
77368 (30 and 60 min.)
b Mean ± S.E.M. of 6 and 4 rats in vehicle and ketotifen groups 
respectively
significantly increased (2.7 ± 0.5) at the 45-60 min period
after RX 77368 injection compared with basal levels (Fig. 21B). 
In ketotifen-treated rats, the hypertensive response induced by 
i.c. injection of RX 77368 was further enhanced by 16 mmHg at 15 
min post injection (P<0.05) and maintained significantly 
increased (96 ± 5 mmHg) at 45 min post injection while the mean 
arterial pressure in vehicle-treated group was returned to basal 
levels (69 ± 5 mmHg) (Fig. 21C). There was no change in gastric 
acid secretion in ketotifen-treated rats injected i.c. with 1.5 
ng of RX 77368 (Table 4.).
3.3.1.4 Discussion
The stable TRH analog, RX 77368, injected i.c. at 1.5 ng 
increased gastric'mucosal blood flow and systemic blood pressure 
while gastric mucosal resistance was decreased during the 15-30 
min post injection in vehicle-pretreated, urethane-anesthetized 
rats. By contrast, there were no changes in gastric acid 
secretion for 30 min following the injection. The vascular 
changes induced by i.c. injection of RX 77368 at 1.5 ng are short 
lasting as shown by the return to basal levels at the 45-60 min 
period post RX 77368 injection (Király 1997b), present data. 
Longer lasting vascular changes were observed after i.c. 
injection of RX 77368 at a higher dose (Tanaka 1993; Király 
1994) . The specificity of the TRH response was previously 
established by the lack of vascular responses upon i.c. injection 
of vehicle (Király 1994; Király 1997b).
Previous reports indicate that the gastric hyperemic 
response to i.c. injection of TRH or RX 77368 is vagal- 
cholinergic mediated (Thiefin 1989; 0-Lee 1997; Király 1998) . In 
the present study, ketotifen, administered at a dose which had no 
effect on basal vascular parameters, prevented i.c. RX 77368 at
1.5 ng induced-increase in gastric blood flow and decrease in 
gastric vascular resistance. Ketotifen is a well established mast 
cell stabilizer as shown by in vivo or in vitro studies in which 
gastrointestinal mast cell activation induced by various
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treatments (toxin A, calcium ionophore, nitric oxide synthase 
inhibitor, substance P, and Helicobacter pylori) was abolished by 
ketotifen (Hogaboam 1993; Kubes 1993; Pothulakis 1993; Gronbech 
1994; Kurose 1994). However, there is evidence in isolated 
intestinal smooth muscle preparations that ketotifen may also act 
as a non selective weak anti-muscarinic receptor antagonist 
(Eltze 1992) although such findings have not been confirmed 
(Abu-Dalu 1996). It is unlikely that the ketotifen inhibitory 
action observed in the present study is related to its weak 
antimuscarinic properties (Eltze 1992) . The atropine-sensitive 
stimulation of other gastric functions (motility at 1.5 ng and 
acid secretion at 30 ng) induced by i.c. injection of RX 77368 is 
not modified by ketotifen under otherwise similar conditions 
(unpublished data)'. Likewise, the acid response to pylorus 
ligation is not altered by intragastric administration of 1-10 
mg/kg of ketotifen (Karmeli 1991; Okabe 1992).
Although we did not investigate directly whether i.c. 
injection of RX 77368 at 1.5 ng induced a vagal cholinergic mast 
cell activation, convergent findings support this hypothesis. 
Electrical vagal stimulation decreased mast cell count in the 
gastric mucosa and submucosa through atropine-sensitive pathways 
in rats (Cho 1977; Cho 1979; Gottwald 1992) . Cold exposure, known 
to stimulate gastric vagal activity through excitation of 
medullary TRH neurons (Niida 1991; Yang 1994), results in a 
cholinergic mediated degranulation of gastric mast cells (Cho 
1979). Likewise, RX 77368 injected i.c. induced a vagal 
muscarinic dependent increase in the intestinal release of 
protease II, (Santos 1996) a specific marker for activated 
mucosal mast cells (Henegan 1984). Connective tissue mast cells 
were also shown to respond directly to a cholinergic receptor 
agonist (Fantozzi 1978; Masini 1985). In addition, the stomach 
contains a dense population of mast cells (Catto-Smith 1995) and 
a close anatomical relationship between mast cells, neurons and 
arteriolar walls has been observed in the gastric and intestinal 
submucosa (Newson 1983; Johnson 1992; Gronbech 1994).
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Mechanisms through which ketotifen prevents the gastric 
hyperemic response to i.c. injection of RX 77368 at 1.5 ng are 
still to be established. However, there is evidence supporting 
the view that ketotifen action may be mediated by preventing mast 
cells-induced activation of capsaicin-sensitive afferent fibers. 
This concept is attractive since capsaicin-sensitive afferent 
fibers containing CGRP are closely apposed to mast cells (Stead 
1987; Stead 1989; Crivellato 1991). In addition, mast cell- 
derived substances such as serotonin, histamine, or prostaglandin 
E2 (Johnson 1992) are capable of sensitizing or activating 
capsaicin-sensitive fibers which are ultimately reflected by the 
release of CGRP (Hua 1993; Akoev 1996). Moreover, we recently 
showed that capsaicin pretreatment or the CGRP receptor 
antagonist, hCGRP8.37 injected i.v. completely abolished i.c. RX 
77368 at 1.5 ng induced gastric hyperemia (Király 1997b) . We also 
obtained preliminary electrophysiological evidence that i.c. 
injection of RX 77368 at 1.5 ng induces an atropine-sensitive 
activation of gastric splanchnic afferent fibers which is 
alleviated by ketotifen (0-Lee 1996) . Taken together, these data 
suggest that the cholinergic dependent gastric hyperemia to 
central TRH, injected at a dose subthreshold to induce an acid 
secretory response, could be brought about by an interaction 
between vagal cholinergic stimulation and gastric mast cell 
response activating efferent function of capsaicin-sensitive 
afferent fibers to release the vasodilatory peptide, CRRP.
Central injection of TRH or TRH analog increases systemic 
blood pressure which is dependent upon sympathetic nervous system 
activation (Mattila 1986; Siren 1988; Thiefin 1989; Király 1998). 
However, while central injection of TRH stimulates splanchnic 
nerve activity in the adrenal and renal branches, there is a 
decrease in the activity in the gastric branch (Tache 1980; 
Somiya 1984; Mattila 1986). In the present study, i.c. injection 
of RX 77368 at 1.5 ng induces a short lasting rise (11 mmHg) in 
systemic blood pressure as previously reported using a similar
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dose of RX 77368 (Király 1997b). The decrease in gastric mucosal 
resistance in the presence of an increase in total systemic 
vascular resistance indicates a local vasodilation of gastric 
mucosal arterioles induced by i.c. RX 77368 at 1.5 ng. In 
ketotifen-treated rats, the rise in mean arterial pressure 
induced by i.c. injection of RX 77368 was of higher magnitude (25 
mmHg) and longer duration (over 45 min) and there was an increase 
instead of a decrease in gastric mucosal vascular resistance. 
Since ketotifen did not influence basal mean arterial pressure, 
these results indicate that mast cells alleviate the systemic 
hypertensive response to i.c. RX 77368 at 1.5 ng most likely 
through the release of vasodilatory transmitters (Hannon 1995). 
Ketotifen induced-blockade of gastric hyperemia is unlikely to be 
the consequence of the rise in systemic arterial blood pressure. 
Central injection of TRH or RX 77368 at higher doses induces 
similar hypertensive responses (28-30 mmHg) while the gastric 
blood flow is increased above 100% and vascular resistance is 
decreased (Thiefin 1989; Király 1994; Király 1998). In addition, 
atropine, vagotomy, capsaicin or CGRP receptor antagonist 
pretreatments abolished central TRH or RX 77368 induced increase 
in blood flow and decrease in vascular resistance in the gastric 
mucosa while the rise in systemic blood pressure was not 
inhibited (Thiefin 1989; Király 1994; Király 1997b; Király 1998). 
The increase in gastric vascular resistance observed after RX 
77368 in rats pretreated with ketotifen (present study), 
capsaicin and CGRP receptor antagonist (Király 1997b) may reflect 
gastric vasoconstriction when local vasodilatory mechanisms are 
blocked by these treatments due to catecholaminergic influence as 
observed in other vascular beds after central injection of TRH 
(Siren 1988).
In summary, stabilization of mast cells by ketotifen 
abolished the gastric hyperemic response to TRH analog injected 
i.c. at a dose subthreshold to stimulate gastric acid secretion. 
These findings suggest a significant role of mast cells in the 
regulation of gastric mucosal blood flow in response to a low
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level of central vagal activation. These observations also 
support the notion that mast cells, in addition to their 
important role in immunological and pathologic processes in the 
gastrointestinal tract (Crowe 1992), may participate in the 
physiological vagal regulation of gastric mucosal blood flow. As 
different stimuli may evoke different patterns of mast cell 
mediator release (Theoharides 1985), further studies are required 
to delineate the mast cell mediators involved as well as the 
exact mechanisms underlying the interaction between mast cells 
and capsaicin-sensitive afferent fibers in response to 
intracisternal injection of the stable TRH analog at low dose.
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4. GENERAL DISCUSSIONS AND CONCLUSIONS
Considerable attention over the years has been directed 
toward understanding the relationship between the central nervous 
system and gastrointestinal functions. In particular the common 
association of stress-related GI mucosal damage with CNS injury 
has supported the hypothesis that the CNS may play a significant 
role in controlling the structural integrity of the GI mucosa. 
The establishment of the presence of family of peptide in both 
the gut and the brain led to speculation that these peptide may 
act as CNS neurotransmitters involved in the control of GI 
functions (Cushing, 1932; Hierlihy 1991).
Several sets of experiment suggested that intact vagal tone 
is essential for the maitenance of gastric mucosal integrity 
(Mozsik 1977; Henegan 1984; Mozsik 1993; Mozsik 1992b) and the 
cytoprotective effect of prostaglandins (Mozsik 1986; Cho 1992), 
acid inhibitors (Mozsik 1986; Cho 1992) and retinoids (Mozsik 
1986) .
TRH is well established to act centrally to induce vagal- 
dependent stimulation of gastric function in several animal 
species (Tache 1988; Travagli 1992; Yang 1993; Okumura 1995; Chan 
1995) . The dorsal motor nucleus of the vagus is the site of 
action of TRH or RX 77368 to stimulate gastric acid secretion, 
mucosal blood flow and motor function through vagal muscarinic 
pathways in rats and cats (Tache 1988; Hornby 1989; McCann 1989; 
Yang 1993; Yoneda 1993a). In addition electrophysiological 
studies have shown that TRH caused a direct postsynaptic 
excitatory effect on dorsal motor nucleus neurons (Rogers 1989; 
McCann 1989; Hornby 1989; Travagli 1992), and when injected into 
the cerebrospinal fluid, TRH increased the efferent activity in 
the gastric branch of the vagus (Somiya 1984).
It was recently shown that the stable TRH analog, RX 77368, 
injected either into the cisterna magna or into the dorsal motor 
nucleus of the vagus at a dose (1.5 ng) below the threshold 
necessary to increase gastric acid secretion prevented gastric
mucosal damage induced by ethanol via vagal cholinergic-mediated 
release of PGE2 (Yoneda 1992; Yoneda 1993b).
Several findings implicated the role of endogenous nitric 
oxide and prostaglandins in the maintenance of the integrity of 
the gastric mucosa (MacNaughton 1989; Whittle 1990) . The increase 
of the gastric mucosal blood flow has been shown to play an 
important role in gastric protection against injurious agents 
(Whittle 1990) . Since there is evidence that ic TRH analog 
stimulates the GMBF through muscarinic and NO-dependent pathways 
(Tanaka 1993) we tested the hypothesis that the L-arginine-NO 
pathway play role in the gastric cytoprotection induced by 
central vagal stimulation. We demonstrated (Chapter 3.1)(Király 
1993; Tache 1994b) that NO synthase inhibitor (L-NAME) injected 
intravenously at & dose that inhibited nitric oxide synthesis 
from L-arginine (Tanaka 1993) and did not influence ethanol- 
induced gastric lesions, while the gastric cytoprotective effect 
of RX 77368 was completely abolished. The action of L-NAME was 
reversed by enantiomerically specific manner by L-arginine but 
not by D-arginine (Király 1993). The protective action of nitric 
oxide is most likely related to its involvement in mediating the 
gastric hyperemic response to central vagal stimulation by TRH. 
Taken together these results endogenous PGE2 and NO (Yoneda 1992; 
Yoneda 1993b) appear to subserve a modulator function in the 
vagal regulation of gastric mucosal integrity.
The crucial importance of the gastric microcirculation is 
thus re-enforced by the current findings that at least two 
chemically and physiologically distinct classes of local 
vasodilator mediators of diverse biochemical origins act in 
concert in the maintenance of mucosal viability (Whittle 1990; 
Holzer, 1992b). Thus we chose the measurement of gastric mucosal 
blood flow by using the hydrogen gas-clearance technique to 
further investigate the peripheral pathways of vagal nerve in the 
regulation of the gastric function.
RX 77368 at maximal acid secretory dose (30 ng) induced
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gastric hyperemia through the activation of vagal efferent 
fibers. The action of TRH analogue at this dose involves vagal 
cholinergic activation of "local effector function" of capsaicin- 
sensitive afferents releasing the vasodilatory peptide CGRP 
(Chapter 3.2.1) (Király 1994), whereas substance P (Chapter 
3.2.1) (Király 1994), VIP (Chapter 3.2.4), histamine acting on H,- 
receptor (Chapter 3.2.2) (Király 1997c) are not the primary 
mediators.
In capsaicin-pretreated rats an alternate route of gastric 
mucosal vasodilation is activated in which nitric oxide seem to 
play as the final mediator (Chapter 3.2.1) (Fig. 18.) (Király 
1994; Király 1998).
TRH analogue injected intracisternally at 1.5 ng (non- *
secretory) dose protects the gastric mucosa against ethanol 
injury (Chapter 3.1) (Yoneda 1992; Kato 1994; Kato 1995b), 
increases GMBF (Chapter 3.2.3) (Király 1997b), while not 
stimulating gastric acid secretion (Chapter 3.2.3), (Yoneda 1992; 
Yoneda 1993b). The gastric hyperemic response is mediated by the 
vasodilatory action of CGRP released from capsaicin sensitive 
afferent nerves. No alternate route is activated in capsaicinized 
rats to induce mucosal hyperemia (Chapter 3.2.3) (Fig. 17) 
(Király 1997b) . The lack of acid response is due to the 
inhibitory influence of vagally released gastric prostaglandins 
and CGRP (Chapter 3.2.3).
Stabilization of mast cells by ketotifen prevents the 
hyperemic response to TRH analog injected i.c. at a 
cytoprotective dose suggesting a significant role of mast cells 
in the regulation of gastric mucosal blood flow in response to a 
low level of central vagal stimulation (Chapter 3.3.1) (Király 
1997a). Thus we hypothetize that mast cells might have role in 
the recruitment the "local effector function" of capsaicin 
sensitive afferent nerve endings after central activation of 
gastric vagal efferent fibers (Fig. 22).
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Fig. 72. Schematic representation of the action of RX 77368 injected at a cytoprotective dose (1.5 ng ic) 
in the dorsal vagal conplex (DVC) to induce vagal muscarinic dependent stimulation of gastric secretion 
of histamine, prostaglandin r, (PGfj) calcitonin gene-related peptide (CGRP) n itr ic  oxide (NO) and gastric 
mucosal blood flow (GMBD through the activation o f mast cells
Király, 119
5. New Findings
1. Our study was the first providing evidence that central 
vagal activation induced by i.c. RX 77368 given at a 
cytoprotective dose increases gastric NO formation. In addition, 
i.v. injection of the NO precursor, L-arginine, dose-dependently 
prevents ethanol-induced gastric lesions whereas the D-arginine, 
has no effect.
2. The findings reported in gastric mucosal blood flow 
studies provide the first evidence to suggest that CGRP 
participates in the peripheral mechanisms responsible for the 
gastric hyperemia induced by central vagal cholinergic 
activation.
3. Our findings were the first suggesting that in capsaicin- 
treated rats, central vagal activation induced by a secretory 
dose of TRH analog (30 ng) increases GMBF by CGRP independent 
mechanisms. By contrast, in intact rats, the gastric hyperemia 
induced by intracisternal injection of TRH analog at the same 
dose involves vagal cholinergic activation of the local "effector 
function" of capsaicin-sensitive fibers releasing the 
vasodilatory peptide CGRP.
4. These data provide the very first evidence that upon 
central vagal activation, there is a cross talk between vagal 
efferent cholinergic pathways and capsaicin sensitive 
(splanchnic) sensory afferent fibers containing CGRP. 5*
5. Our studies were the first showing that depending upon
the level of central stimulation of the vagus alternate 
peripheral routes / or cascades are recruited and come into play
to induce hyperemia in the mucosa.
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6. The results were the first demonstration that [4C1-D- 
Phe6, Leu17] VIP is an antagonist for VIP-induced systemic or gastric 
vascular changes in the rat.
7. Under activation of medullary preganglionic vagal 
neurons, the underlying mechanisms increasing GMBF does not 
involved NANC VIP mediated mechanisms. 8
8. We provided the first functional evidence that the 
communication between vagal efferents and splanchnic sensory 
afferents is mediated by activated gastric mucosal mast cells .
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